WO2024008102A1 - Linker for conjugation - Google Patents
Linker for conjugation Download PDFInfo
- Publication number
- WO2024008102A1 WO2024008102A1 PCT/CN2023/105774 CN2023105774W WO2024008102A1 WO 2024008102 A1 WO2024008102 A1 WO 2024008102A1 CN 2023105774 W CN2023105774 W CN 2023105774W WO 2024008102 A1 WO2024008102 A1 WO 2024008102A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- integer
- linker
- drug
- compound
- mmol
- Prior art date
Links
- 230000021615 conjugation Effects 0.000 title description 13
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 105
- 150000001875 compounds Chemical class 0.000 claims description 73
- 239000000611 antibody drug conjugate Substances 0.000 claims description 62
- 229940079593 drug Drugs 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 62
- 125000005647 linker group Chemical group 0.000 claims description 47
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 claims description 19
- 229950009429 exatecan Drugs 0.000 claims description 19
- 239000000562 conjugate Substances 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 230000001268 conjugating effect Effects 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 229960000575 trastuzumab Drugs 0.000 claims description 6
- 229910003827 NRaRb Inorganic materials 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 129
- -1 linker compound Chemical class 0.000 description 107
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 74
- 239000000203 mixture Substances 0.000 description 71
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- 239000011347 resin Substances 0.000 description 43
- 229920005989 resin Polymers 0.000 description 43
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 34
- 238000003776 cleavage reaction Methods 0.000 description 33
- 230000007017 scission Effects 0.000 description 33
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 23
- WXNSCLIZKHLNSG-MCZRLCSDSA-N 6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide Chemical class CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[C@H](NC(=O)COCNC(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)CNC(=O)CCCCCN5C(=O)C=CC5=O)C3=C14)C2=O WXNSCLIZKHLNSG-MCZRLCSDSA-N 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 239000000872 buffer Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 19
- 238000005859 coupling reaction Methods 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 11
- 102000004225 Cathepsin B Human genes 0.000 description 11
- 108090000712 Cathepsin B Proteins 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 230000002194 synthesizing effect Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 6
- PTUJJIPXBJJLLV-UHFFFAOYSA-N 2-[[2-[[2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(=O)NCC(=O)NC(C(=O)NCC(O)=O)CC1=CC=CC=C1 PTUJJIPXBJJLLV-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 230000005587 bubbling Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 4
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- VCQGDYBYGWVBES-UHFFFAOYSA-N benzyl 2-(2-hydroxyethoxy)acetate Chemical compound OCCOCC(=O)OCC1=CC=CC=C1 VCQGDYBYGWVBES-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 4
- 229940127093 camptothecin Drugs 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- CNKWSDPXBSSSPJ-UHFFFAOYSA-N 2-(2-hydroxyethoxy)propanoic acid Chemical compound OC(=O)C(C)OCCO CNKWSDPXBSSSPJ-UHFFFAOYSA-N 0.000 description 3
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 3
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000007030 peptide scission Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 2
- BHPSIKROCCEKQR-UHFFFAOYSA-N 3-sulfanylpyrrole-2,5-dione Chemical compound SC1=CC(=O)NC1=O BHPSIKROCCEKQR-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- ZYTLPUIDJRKAAM-QMMMGPOBSA-N benzyl (2s)-2-hydroxypropanoate Chemical compound C[C@H](O)C(=O)OCC1=CC=CC=C1 ZYTLPUIDJRKAAM-QMMMGPOBSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000009884 interesterification Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- LLAZQXZGAVBLRX-UHFFFAOYSA-N methyl 2,5-dioxopyrrole-1-carboxylate Chemical compound COC(=O)N1C(=O)C=CC1=O LLAZQXZGAVBLRX-UHFFFAOYSA-N 0.000 description 2
- 108010093470 monomethyl auristatin E Proteins 0.000 description 2
- 108010059074 monomethylauristatin F Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 description 1
- FBKUOPULLUJMOC-UHFFFAOYSA-N 2-[[2-(9h-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 FBKUOPULLUJMOC-UHFFFAOYSA-N 0.000 description 1
- LIBCNUNKCWYZAX-UHFFFAOYSA-N 2-[[[2-(9H-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]methoxy]acetic acid Chemical compound OC(=O)COCNC(=O)CNC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 LIBCNUNKCWYZAX-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- YJYAGNPMQVHYAH-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethanol Chemical compound CC(C)(C)[Si](C)(C)OCCO YJYAGNPMQVHYAH-UHFFFAOYSA-N 0.000 description 1
- FWOHDAGPWDEWIB-UHFFFAOYSA-N 2-bromoethoxymethylbenzene Chemical compound BrCCOCC1=CC=CC=C1 FWOHDAGPWDEWIB-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 102000043279 ADAM17 Human genes 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102000013135 CD52 Antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- KSSJBGNOJJETTC-UHFFFAOYSA-N COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC Chemical compound COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC KSSJBGNOJJETTC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 229940123329 Cathepsin B inhibitor Drugs 0.000 description 1
- 229940123003 Cathepsin inhibitor Drugs 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- AZVARJHZBXHUSO-UHFFFAOYSA-N Duocarmycin A Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC(C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-UHFFFAOYSA-N 0.000 description 1
- VQNATVDKACXKTF-UHFFFAOYSA-N Duocarmycin SA Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C(C64CC6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100035139 Folate receptor alpha Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000829127 Homo sapiens Somatostatin receptor type 2 Proteins 0.000 description 1
- 101000829153 Homo sapiens Somatostatin receptor type 5 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
- FONIWJIDLJEJTL-UHFFFAOYSA-N N(8)-acetylspermidine Chemical compound CC(=O)NCCCCNCCCN FONIWJIDLJEJTL-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100023802 Somatostatin receptor type 2 Human genes 0.000 description 1
- 102100023806 Somatostatin receptor type 5 Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RDRDBYYUPACJJT-UHFFFAOYSA-N benzyl 3-hydroxypropanoate Chemical compound OCCC(=O)OCC1=CC=CC=C1 RDRDBYYUPACJJT-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229960005519 duocarmycin A Drugs 0.000 description 1
- 229960005510 duocarmycin SA Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229930187626 hemiasterlin Natural products 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940125493 loncastuximab tesirine-lpyl Drugs 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- AZVARJHZBXHUSO-DZQVEHCYSA-N methyl (1R,4R,12S)-4-methyl-3,7-dioxo-10-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-DZQVEHCYSA-N 0.000 description 1
- ATCCIZURPPEVIZ-BYPYZUCNSA-N methyl (2s)-3-hydroxy-2-methylpropanoate Chemical compound COC(=O)[C@@H](C)CO ATCCIZURPPEVIZ-BYPYZUCNSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to the field of drug conjugates, and more particularly, antibody-drug conjugates.
- ADCs Antibody-drug conjugates
- An ADC is essentially a three component system comprising a potent drug substance linked via a degradable or non-degradable (cleavable/non-cleavable) linker to an antibody, usually monoclonal antibody mAb.
- an ADC Upon binding to the antigen on a cell, an ADC usually is internalized, and then under the intracellular conditions, the drug is released from the antibody to take effects. Comparing to small molecules, number of ADC molecules reaching target cells are smaller, and internalization rate is also slower. Therefore a quick cleavage of the linker to release drug is desirable.
- a linker plays a very important role in an ADC, such as in terms of ADC stability and drug release mechanism.
- An enzyme-assisted cleavable linker such as the one in Trastuzumab deruxtecan usually comprises a short peptide (e.g., 2 ⁇ 4 amino acids) that is cleaved in lysosome once the ADC is internalized, allowing drug to be released for its cell-killing effects. How fast the linker is cleaved by an enzyme (or enzymes) thus determines how fast the drug takes effects in an already-slow ADC mechanism of action.
- Cleavable linkers are used in most ADCs to date due to their ability of quick release of drugs in target cells.
- brentuximab vedotin trastuzumab deruxtecan loncastuximab tesirine-lpyl all use peptidyl cleavage fragments, VC, GGFG, VA, respectively. These peptides are cleaved mainly by enzymes of the cathepsin family (cathepsin B mainly) in lysosome. The rates of cleavage vary, depending on multiple factors, including the nature of enzymes involved, the region-specification enzyme-substrate interaction, etc.
- the linker of Trastuzumab deruxtecan contains a tetrapeptide GGFG, wherein the amide bond of the last amino acid glycine serves as the scissile bond for cleavage by lysosomal protease (e.g., cathepsin family) .
- the rate of cleavage in the case of GGFG is not as fast as in VC.
- the inventors designed a series of linkers, which are suitable for producing linker-payloads and ADCs with improved properties, such as increased cleavability (e.g., as demonstrated by an improved rate of cleavage) , DAR distribution, homogeneity, stability and/or therapeutically relevant efficacy.
- the linkers and the linker-payloads comprising same allow for manufacturing ADCs via a process with improved operability and productivity, such as provision of cleaner ADC products with decreased level of leftover un-conjugated linker-payloads and/or easier removal of the leftover linker-payloads.
- L 1 is - (CH 2 ) a -, wherein a is an integer from 0 to 10, or - (CH 2 CH 2 O) b -, wherein b is an integer from 1 to 36;
- L 2 is - (CH 2 ) c -, wherein c is an integer from 1 to 10, or - (CH 2 CH 2 O) d -, wherein d is an integer from 1 to 36;
- L 3 is absent, or is - (CH 2 ) e -, wherein e is an integer from 1 to 10, or - (CH 2 CH 2 O) f -, wherein f is an integer from 1 to 36;
- R 2 is -H, -C 1-6 alkyl, or -O (CH 2 ) h CH 3 , wherein h is an integer from 0 to 3;
- X is halo, -OR 3 or -NR 4 R 5 ;
- R 3 is -H, -C 1-6 alkyl or halo
- R 4 and R 5 are independently -H or -C 1-6 alkyl
- n 0 or 1
- an antibody-drug conjugate of formula III is provided herein:
- a method of producing a linker-payload compound comprising conjugating a drug with a linker compound of the invention.
- the drug is exatecan.
- an antibody-drug-conjugate comprising
- step (b) conjugating an antibody with the linker-payload compound obtained in step (a) .
- Figure 1 A scheme of synthesizing linker-payload compound (also referred to as ′′Deruxtecan analog′′ in the figures) 1-7 according to a representative example of the invention.
- Figure 2 A scheme of synthesizing linker-payload compound 3-1 according to another representative example of the invention.
- Figure 3 A scheme of synthesizing linker-payload compound 1-1 according to another representative example of the invention.
- Figure 4 A scheme of synthesizing linker-payload compound 1-2 according to another representative example of the invention.
- Figure 5 A scheme of synthesizing linker-payload compound 1-3 according to another representative example of the invention.
- Figure 6 A scheme of synthesizing linker-payload compound 1-4 according to another representative example of the invention.
- Figure 7 A scheme of synthesizing linker-payload compound 1-8 according to another representative example of the invention.
- Figure 8 A scheme of synthesizing linker-payload compound 3-4 according to another representative example of the invention.
- Figure 9 (a) A schematic depiction of the site of modification (circled) and the site of cleavage (dash line) in a linker-payload compound of the invention in comparison with the native linker payload; and (b) percentage (%) of cleavage over time for the linker-payload of the invention in comparison with the native liker-payload.
- Figure 10 (a) A schematic depiction of the site of modification (circled) and the site of cleavage (dash line) in an ADC comprising a linker-payload moiety of the invention in comparison with an ADC comprising the native linker payload moiety; and (b) percentage (%) of cleavage over time for the linker-payload moiety of the invention in ADC in comparison with cleavage of the native liker-payload moiety in ADC.
- Figure 11 Binding affinity of ADCs comprising different linker-payload moieties to antigen Her2 on different cell lines.
- Figure 12 Cytotoxicity of ADCs comprising different linker-payload moieties on different cell lines.
- a value or value range with or without being preceded by the term “about” or “approximately” covers equivalents within a reasonable range of approximation as can be understood by an artisan in the related field, such as a range of ⁇ 10%, ⁇ 5%, ⁇ 3%, ⁇ 2%, ⁇ 1%or ⁇ 0.5%around the specified value.
- the terms ′′substantially no′′ and ′′substantially free (of) ′′ with regard to presence of a scenario or a substance not only refers to absence (i.e., ′′no′′ , ′′zero′′ or ′′free (of) ′′ ) but also refers to a presence of insignificance or a presence or an amount below the limit of an assay and thus undetectable. This can be well understood by a skilled person in the art.
- the cleavage rate of peptide linkers depends on multiple factors, such as the nature of enzymes as involved, region-specific enzyme-substrate interaction, etc.
- linker-payloads of the invention comprising the designed linker moieties exhibited increased cathepsin B cleavage rate, either as a solitary compound or a moiety in an ADC, compared to a reference comprising an analogous existing linker moiety. It was observed that the designed linkers are more prone to enzyme cleavage, which helps to improve efficacy of ADCs.
- ADCs comprising the linker-payload moieties of the invention may exhibit an increased stability (e.g., storage stability, such as freeze-thaw stability) and/or a comparable or even better therapeutically relevant efficacy (e.g., binding affinity and/or cytotoxicity) as compared to an existing analogous ADC.
- stability e.g., storage stability, such as freeze-thaw stability
- efficacy e.g., binding affinity and/or cytotoxicity
- linker-payloads of the invention comprising the designed linker moieties can provide a cleaner product, for example, as compared with at a high drug-antibody ratio (DAR) .
- DAR of is 7.5.
- more linker-payload is needed in the conjugation reaction.
- removal of the leftover linker-payloads can be onerous.
- the linker-payloads of the invention can be more easily and completely removed, for example, as compared to deruxtecan in Enhertu, and thereby can yield cleaner ADC products. This might be explained by increased hydrophilicity of the linker-payloads of the invention.
- linkers and linker-payloads of the present invention can provide ADC products with improved homogeneity.
- ADCs prepared using the linker-payloads of the invention can be more easily purified.
- the free linker-payloads left in the ADC products after conjugation are significantly decreased, for example, as compared to products produced using the linker-payload used in Accordingly, the linkers and the linker-payloads of the present invention allow for producing ADCs with improved purity, and also allow for manufacturing ADCs via a process with improved operability and productivity.
- the term ′′linker′′ may refer to either a solitary linker compound of the invention or a linker moiety as incorporated into and thus as part of a linker-payload conjugate or an antibody-drug conjugate according to the present invention.
- a linker moiety refers to the moiety derived from the corresponding linker compound when being incorporated in the conjugates via conjugation.
- the present invention provides a linker compound having the structure of formula I:
- L 1 is - (CH 2 ) a -, wherein a is an integer from 0 to10, preferably from 1 to 8, more preferably from 2 to 6 or from 4 to 5, or - (CH 2 CH 2 O) b -, wherein b is an integer from 1 to 36, preferably from 2 to 30, more preferably from 3 to 25 or from 4 to 20;
- L 2 is - (CH 2 ) c -, wherein c is an integer from 1 to 10, preferably from 1 to 8 or 1 to 6, more preferably, from 1 to 2; or - (CH 2 CH 2 O) d -, wherein d is an integer from 1 to 36, preferably from 2 to 30, more preferably from 3 to 25 or from 4 to 20;
- L 3 is absent, or is - (CH 2 ) e -, wherein e is an integer from 1 to 10, preferably from 1 to 8 or 1 to 6, more preferably from 1 to 2, or - (CH 2 CH 2 O) f -, wherein f is an integer from 1 to 36 preferably from 1 to 20, more preferably from 1 to 2, from 3 to 25 or from 4 to 20;
- R 2 is -H, -C 1-6 alkyl, or -O (CH 2 ) h CH 3 , wherein h is an integer from 0 to 3, preferably R 2 is -H or -CH 3 ;
- X is halo, -OR 3 or -NR 4 R 5 , preferably -OR 3;
- R 3 is -H, -C 1-6 alkyl or halo, preferably -H, -CH 3 , t-butyl or Cl;
- R 4 and R 5 are independently -H or -C 1-6 alkyl
- n 0 or 1
- linker compounds include Compounds L-1-1, L-1-2, L-1-3, L-1-4, L-1-7, L-1-8, L-3-1 and L-3-4 as shown below, or a pharmaceutically acceptable salt or ester thereof:
- the designed linkers provide unique features and chemical properties.
- a CF 3 group is introduced to the alpha position of an amine residue to generate a strong dipolar moiety at the N-side of the GGFG peptide.
- This group most likely reduces Km of cathepsin B-GGFG interaction and thus accelerates the enzymatic catalysis rate of the hydrolysis of the peptide.
- introduction of tetra-amine or acetyl amine at the similar position of the linker e.g., as in L-3-1 and L-3-4) also leads to the catalytic rate increase.
- ′′linker-payload′′ (also referred to as ′′LP′′ for short herein below) , as can be understood from the context, may refer to either a solitary linker-payload compound of the invention or a linker-payload moiety as incorporated into and thus as part of an antibody-drug conjugate according to the present invention.
- a linker-payload moiety may share the same numeral code with the corresponding linker-payload compound from which it derives via conjugation.
- the term ′′linker-payload compound′′ refers to a conjugate compound composed of a linker moiety covalently conjugated to a drug moiety, wherein the drug moiety is also known as ′′payload′′ .
- the linker-payload compound may further be conjugated to an antibody to thereby provide an ADC comprising the linker-payload moiety of the invention.
- the present invention provides a linker-payload conjugate having the structure of formula II:
- the linker-payload conjugate may be a compound having any one of the following formulae, or a pharmaceutically acceptable salt or ester thereof:
- the Drug useful in the present invention is not particularly limited, as long as it possesses or can be modified to possess a functionality group for conjugation with the linker compound at the end opposite to the maleimide moiety.
- the functionality group for conjugation may be -NHR, wherein R is an alkyl or H.
- the term ′′drug′′ may refer to either a drug that forms the drug moiety covalently conjugated to the linker moiety in a linkier-payload compound or an ADC, or a drug that is released from a linker-payload or an ADC via enzymatic cleavage.
- Drugs useful in the present invention include cytotoxic drugs, particularly those used in cancer therapy.
- cytotoxic drugs include, but are not limited to, DNA damaging agents, DNA binding agents, nucleic acid synthesis inhibitors, transcription inhibitors, anti-metabolites, enzyme inhibitors such as thymidylate synthase inhibitors and topoisomerase inhibitors, tubulin inhibitors and toxins such as toxins of a bacterial, fungal, plant or animal origin.
- taxol methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin, doxorubicin, mitomycin C, mitomycin A, caminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vinblastine, vincristine, vindesine, taxanes including taxol, taxotere retinoic acid, butyric acid, N8-acetyl spermidine, camptothecin, calicheamicin, esperamicin, ene-diynes, duocarmycin A, duocarmycin SA, calicheamicin, camptothecin, hemiasterlin
- the drug is topoisomerase inhibitor, such as camptothecin, irinotecan, topotecan, exatecan, etoposide and derivatives thereof, like hodroxycamptothecin and Dxd.
- the drug is Dxd.
- the drug is exatecan.
- the drug is Dxd, when being released from the linker-payload or the ADC.
- the drug is exatecan, when being conjugated with the linker to form the drug moiety.
- the linker-payload conjugate may be a compound having the structure of formulae IIa, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof:
- the linker-payload conjugate may be a compound selected from the group consisting of Compounds 1-1, 1-2, 1-3, 1-4, 1-7, 1-8, 3-1 or 3-4 as shown below, or a pharmaceutically acceptable salt or ester thereof:
- a method of producing a linker-payload conjugate compound comprising conjugating a drug with a linker compound of the invention.
- the drug is exatecan.
- Conjugating a drug with a linker compound can be carried out via a coupling reation (e.g., esterification reaction or amidation reaction) or interesterification reaction as known in the art, depending on the type of the functional group (s) at the terminal end of the linker compound and the type of the functional group (s) on the drug.
- the present invention provides an antibody-drug conjugate comprising an antibody conjugated with one or more drug molecules via a linker moiety of the invention, which may be represented by formula III:
- p is 1 to 8, such as 1, 2, 3, 4, 5, 6, 7 and 8; in some embodiments, p is 2, 4 or 6; and in some embodiments, p is 4.
- the antibody can be of any specificity, configuration and origins.
- the antibody specifically binds to a tumor antigen (TA) , such as a tumor specific antigen (TSA) and a tumor-associated antigen (TAA) .
- TSA tumor specific antigen
- TAA tumor-associated antigen
- tumor antigen examples include, but are not limited to, CD20, CD38, CD123, ROR1, ROR2, BCMA, PSMA, SSTR2, SSTR5, CD19, FLT3, CD33, PSCA, ADAM 17, CEA, Her2, EGFR, EGFR-vIII, CD30, FOLR1, GD-2, CA-IX, Trop2, CD70, CD38, mesothelin, EphA2, CD22, CD79b, GPNMB, CD56, CD138, CD52, CD74, CD30, CD123, RON, and ERBB2.
- TA-specific antibodies include, but are not limited to, Trastuzumab, Rituximab, Cetuximab, Bevacizumab, Panitumumab, Alemtuzumab, Matuzumab, Gemtuzumab, Polatuzumab, Inotuzumab, etc.
- the antibody (Ab) is Trastuzumab.
- the term ′′antibody′′ includes fragments of antibody, such as Fab fragments, Fab′ fragments, F (ab′) 2 fragments, Fv fragments and scFv fragments. Further, the term ′′antibody′′ may extend to include functional equivalents such as ligands and binding proteins that specifically recognize and bind to a target molecule such as an antigen (e.g., tumor antigens) , a receptor or other surface molecules on a targeted cell, such as pathology-associated cells, like cancer or tumor cells, as long as the equivalent molecule possesses or can be modified to possess a functionality group that can react with the maleimide moiety of the linker and thereby covalently binding to the linker.
- the functionality group is a thiol group, such as those released via reduction of inter-chain disulfides, so that the antibody can be conjugated to the linker moiety via a thio-maleimide linkage.
- the present invention provides a method of producing an antibody-drug-conjugate, comprising conjugating an antibody with a linker-payload compound of the invention.
- the method may comprises:
- step (b) conjugating an antibody with a linker-payload compound obtained in step (a) .
- Step (a) can be carried out via a coupling reation (e.g., esterification reaction or amidation reaction) or interesterification reaction as known in the art, depending on the type of the functional group (s) at the terminal end of the linker compound and the type of the functional group (s) on the drug.
- a coupling reation e.g., esterification reaction or amidation reaction
- interesterification reaction as known in the art, depending on the type of the functional group (s) at the terminal end of the linker compound and the type of the functional group (s) on the drug.
- Step (b) can be carried out by reacting a maleimido moiety with a free thiol group from the antibody via Michael addition reaction.
- the free thiol group (s) may come from the cysteine residue (s) , such as those released by reduction of an inter-chain disulfide bond, so that the antibody can be conjugated to the linker moiety via a thio-maleimide linkage.
- the antibody-drug-conjugate of the invention can be formulated with a pharmaceutically acceptable excipient to provide a pharmaceutical composition.
- the composition may comprise a therapeutically effective amount of the antibody-drug-conjugate.
- the composition may comprise an effective amount of the antibody-drug-conjugate that allows for obtaining a dosage as desired.
- the antibody-drug conjugate of the invention can be used for treating a disease, disorder or condition in a subject in need thereof, wherein the treatment may comprise administrating to the subject a therapeutically effective amount of the antibody drug-conjugate.
- an antibody-drug conjugate according to the present invention for use in treatment of a disease, disorder or condition in a subject in need thereof.
- the disease to be treated may include but are not be limited to cancers, including solid tumors and hematopoeitic malignancies.
- cancers include but are not limited to breast cancers, gastric cancers, pancreatic cancers, hepatic cancers, lung cancers (e.g., NSCLC) , head and neck cancers, colorectal cancers, B cell lymphomas (e.g., non-Hodgkin’s lymphoma (NHL) ) and leukemia.
- NSCLC non-Hodgkin’s lymphoma
- the term “subject” refers to a human or a non-human animal subject.
- Non-human animals may be mammals, such as primates.
- Examples of non-human animal subjects include but are not limited to domestic animals, farm animals, and zoo, sports, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, swine, cows, and bears.
- the subject is a human.
- a ′′subject in need thereof′′ refers to a subject in need of diagnosis, prognosis, amelioration, prevention and/or treatment of a disease, disorder or condition.
- Step 1 methyl 2- (2- ( (tert-butyldimethylsilyl) oxy) ethoxy) acetate (a-1)
- the intermediate was de-TBS at 1 M HCl (5.00 mL) .
- Step 3 benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate (a-4)
- Step 4 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oic acid (a-5)
- Step 5 (a-6, i.e., L-1-7)
- Fmoc-Phe-OH (0.58g, 1.31 mmol) was added and mixed for 30 secs, then O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate (HBTU) (0.54 g, 1.43 mmol) and N, N-diisopropylethylamine (0.25 g, 1.95 mmol) in N, N-Dimethylformamide were added, and bubbled by nitrogen for 30 mins. The resin was washed with N,N-Dimethylformamide for 3 times.
- HBTU O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate
- HBTU O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate
- N, N-diisopropylethylamine (0.25 g, 1.95 mmol
- Step 1 benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate (b-3)
- Step 2 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid (a-3)
- Step 3 (S) -2-amino-6- ( (tert-butoxycarbonyl) amino) hexanoic acid (b-6)
- Step 4 (S) -6- ( (tert-butoxycarbonyl) amino) -2- (dimethylamino) hexanoic acid (b-7)
- Step 5 (S) -2- (dimethylamino) -6- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) hexanoic acid (b-9)
- the colorless oil was dissolved in saturation sodium bicarbonate (6.00 mL) at 0 °C, after, methyl 2, 5-dioxo-2, 5-dihydro-1H-pyrrole-1-carboxylate (407 mg, 2.62 mmol) was added to the reaction mixture and stirred for 0 °C at 1 hr and then kept at 25 °C for another 3 hrs.
- LC-MS showed intermediate was consumed completely and one main peak with desired mass was detected.
- the reaction mixture was acidized by addition 1 M HCl (5.00 mL) and purified by Flash (Eluent of 10 ⁇ 50%H 2 O (0.1%TFA) /CH 3 CN on C-18 column chromatography) .
- Step 6 (3S, 12S) -12-benzyl-3- (4- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) butyl) -2-methyl-4, 7, 10, 13, 16-pentaoxo-19-oxa-2, 5, 8, 11, 14, 17-hexaazadocosan-22-oic acid (b-10, i.e., L-3-1)
- Fmoc-Phe-OH (0.58g, 1.31 mmol) was added and mixed for 30 secs, then O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate (HBTU) (0.54 g, 1.43 mmol) and N, N-diisopropylethylamine (DIEA) (0.25 g, 1.95 mmol) in N, N-Dimethylformamide were added and bubbled by N 2 for 30 mins. The resin was washed with N, N-Dimethylformamide for 3 times.
- HBTU N, N-tetramethyl-uronium-hexafluorophosphate
- DIEA N-diisopropylethylamine
- cleavage buffer (20%HFIP/80%DCM) was added to the flask containing the resin of peptide, stirred for 2 mins for 2 times. The HFIP-mixture was removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H 2 O/CH 3 CN on C-18 column chromatography) .
- Step 1 10-benzyl-23- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -6, 9, 12, 15-tetraoxo-18- (trifluoromethyl) -3-oxa-5, 8, 11, 14, 17-pentaazatricosan-1-oic acid (c-1, i.e., L-1-1)
- the peptide was synthesized using standard Fmoc chemistry.
- the reaction mixture was purified by prep-HPLC (natural condition, pure water) directly, two peaks with desired mass was detected in perp-HPLC, separated and lyophilized to obtained Deruxtecan analog 1-1 (Peak 1: 1.4 mg, 85.97%purity, Peak 2: 7.1 mg, 90.32%purity, 22.3%yield) as a white solid.
- Step 1 (S) -benzyl 1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oate (d-3)
- Step 2 (S) -1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oic acid (d-4)
- Step 3 (2S, 10S) -10-benzyl-23- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-6, 9, 12, 15-tetraoxo-18- (trifluoromethyl) -3-oxa-5, 8, 11, 14, 17-pentaazatricosan-1-oic acid (d-5, i.e., L-1-2)
- Fmoc-Phe-OH (1.50 mmol) was added and mixed for 30 secs, then O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate (HBTU) (1.50 mmol) and N, N-diisopropylethylamine (DIEA) (3.00 mmol) in N, N-Dimethylformamide were added, and bubbled by N 2 for 30 mins. The resin was washed with N, N-Dimethylformamide for 3 times.
- HBTU N, N-tetramethyl-uronium-hexafluorophosphate
- DIEA N-diisopropylethylamine
- Step 1 benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate (e-3)
- Step 2 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid (e-4)
- Step 3 (11S) -11-benzyl-24- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -7, 10, 13, 16-tetraoxo-19- (trifluoromethyl) -4-oxa-6, 9, 12, 15, 18-pentaazatetracosan-1-oic acid (e-5, i.e., L-1-3)
- Step 1 (S) -methyl 1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate (f-3)
- Step 2 (S) -1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid (f-4)
- Step 3 (11S) -11-benzyl-24- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-7, 10, 13, 16-tetraoxo-19- (trifluoromethyl) -4-oxa-6, 9, 12, 15, 18-pentaazatetracosan-1-oic acid (f-5, i.e., L-1-4)
- Step 1 benzyl 2- (2- (benzyloxy) ethoxy) propanoate (g-2)
- the reaction mixture was quenched by addition water (1000 mL) at 0°C, and extracted with dichloromethane (200 mL x 3) .
- the combined organic layers were washed with brine (200 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue.
- Step 4 benzyl 1- (9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate (g-6)
- Step 5 1- (9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oic acid (g-7)
- Step 6 (13S) -13-benzyl-26- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-9, 12, 15, 18-tetraoxo-21- (trifluoromethyl) -3, 6-dioxa-8, 11, 14, 17, 20-pentaazahexacosan-1-oic acid (g-8, i.e., L-1-8)
- the peptide was synthesized using standard Fmoc chemistry.
- a cleavage buffer (20%HFIP /DCM) was added to the peptide Resin, and stirred for 0.5 hr for 3 times.
- Step 1 (S) -2-acetamido-6- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) hexanoic acid (h-3)
- Step 2 (19S) -10-benzyl-19- (4- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) butyl) -6, 9, 12, 15, 18, 21-hexaoxo-3-oxa-5, 8, 11, 14, 17, 20-hexaazadocosan-1-oic acid (h-4, i.e., L-3-4)
- the peptide was synthesized using standard Fmoc chemistry.
- ′′native linker-payload′′ (also referred to as ′′native-LP′′ or ′′nat-LP′′ herein below) refers to a compound having the following structure:
- the native-LP has the same structure as Deruxtecan in Enhertu, both containing the maleimide-GGFG pepetide linker.
- the native-LP was purchased under the name ′′Deruxtecan′′ from MedChemExpress.
- Antibody-drug conjugates were synthesized according the following general procedure: an antibody in a pH7 PBS solution was first reduced by 2 ⁇ 20 equivalent of TCEP for a period of time raging from 0.5 to 18 hrs; with or without removal of residual TCEP by column or membrane, a linker-load in excess (15 ⁇ 18 molar excess) was introduced; the conjugation reaction was finished in half to several hours at a temperature ranging from 4°C to RT, followed by HPLC purification to provide the final ADC product.
- Reaction buffer 40 mM H 3 PO 4 /H 3 BO 3 /HAc, 1 mM EDTA, pH 4.5
- sample 0.015 ⁇ mol linker-payload compound
- cathepsin B 16 U/ ⁇ mol linker-payload compound
- cleavage site and modification on the linker moiety in Compound 1-1 were indicated in panel (a) , as in comparison with the native linker-payload; and percentages (%) of cleavage are shown in panel (b) , wherein the percentages were calculated based on the peak areas of released drugs as detected by reverse-phase HPLC (mixed mode) chromatogram.
- the linker-payloads of the invention were digested faster.
- reaction conditions were set the same as in Example 3 for hydrolysis of linker-payloads per se. Specifically, reaction buffer (40 mM H 3 PO 4 /H 3 BO 3 /HAc, 1 mM EDTA, pH 4.5) , 135 mM Cysteine, DMA (2%, v/v) , sample (0.015 ⁇ mol ADC) and cathepsin B (16 U/ ⁇ mol ADC) were added in sequence into a 1.5 mL EP vial. The final cysteine concentration in the 300 ⁇ L hydrolysis system was 10 mM. The EP vial was placed in a 37°C water bath.
- cleavage site and modification in comparison with the native linker-payload moiety in ADC are indicated in panel (a) , and percentage (%) of cleavage of the linker-payloads in ADCs over time is shown in panel (b) , wherein the percentages were calculated based on the peak areas of released drugs (supra) .
- the hydrolysis percentage was 18.5%for ADC-1-1 (i.e. ADC comprising linker-payload moiety 1-1) , while 15.5%for ADC-native LP.
- ADC samples ( ⁇ 10mg/mL in 20 mM Histidine, 150mM NaCl, pH6.0) in Eppendorf tubes were taken out from a -80°C freezer and thawed at room temperature for 30 min. The ADC samples were then frozen at -80°C for 2 days and thawed at room temperature for 30 min; and the freeze/thaw process was repeated one more time. After that, 20 ⁇ l of each sample was subjected to SEC and MS to measure DAR and drug distribution.
- the ADC comprising linker-payload moiety 1-8 exhibited the lightest DAR drop after two freeze-and-thaw cycles. Overall, the eight ADC analogs all contained less undesired H4 than Her-Dxd while maintained stable DAR after Freeze-and-thaw cycles.
- ′′Her′′ ′′Herceptin′′ , aka. ′′Trastuzumab′′ ; and ′′Fresh′′ refers to the samples of newly synthesized ADCs that were not subjected to the freeze-and-thaw cycles yet.
- ADCs were formulated in 20 mM Histidine buffer comprising 150mM NaCl, pH6.0.
- the obtained ADC samples were subjected to LC-MS analysis to determine drug distribution on light and heavy chains. Ideally, only 5 species, L0, H0, L1, H1 and H2, can be found. Aggregation percentage was determined by HPLC.
- Table 4 shows a comparison of the non-specific and unwanted H4%among ADCs.
- H4%(molar ratio) was 3%after synthesis, while in the case of Her-1-8, the unwanted species was significantly decreased to 0.8%.
- ADC products produced with the linker-payloads of the invention contain less unwanted species.
- the ADCs were buffer exchanged into 20 mM Histidine buffer comprising 150mM NaCl (pH6.0) via spin desalting column (40 kDa) .
- Table 5 is a comparison among ADCs using different linker-payloads on removal of free linker-payloads (i.e., un-conjugated linker-payloads) .
- the free linker-payloads were removed via UFDF.
- the conjugation product had an amount of residual free linker-payload approaching 5%, while in the case of products produced using the linker-payloads of the invention, the amount was 2%or less.
- the linker-payloads of the invention provide improved operability in purification, for instance, by allowing for an easier and more complete removal of residual free linker-payloads from an ADC conjugation product.
- introduction of the dipolar moiety to the linker moiety increases water solubility of the linker-payload and facilitates its removal, e.g., by UFDF. This property is meaningful for the process of ADC manufacturing.
- Binding to human HER2 in vitro were assayed by FACS (Fluorescence Activated Cell Sorting) .
- FACS Fluorescence Activated Cell Sorting
- tumor cells expressing HER-2 (1 ⁇ 10 5 cells/well) were incubated with serially-diluted ADCs for 1-2 hours at 4°C.
- Her-Dxd, prepared as described in Example 2 was used as the reference ADC and positive control.
- the buffer used to dissolve the ADCs (20 mM Histidine buffer comprisng 150mM NaCl (pH6.0) ) was used as the negative control.
- the cells were washed with the FACS staining buffer, and then the secondary antibody Alexa647-conjugated goat anti-human IgG Fc (Jackson) diluted in the FACS staining buffer was added. The plates were incubated at 4°C for 20-60 minutes in dark. Then, fluorescence intensity was measured on flow cytometer (BD FACS Canto II) and data analyzed by FlowJo software. The EC 50 values were calculated using GraphPad Prism software.
- results were shown in FIG. 11.
- the test ADCs of the invention were observed with an EC 50 around 1nM, while 0.9 nM for Her-Dxd.
- the test ADCs of the invention were observed with an EC 50 of 0.4 ⁇ 0.7nM, while 0.4 nM for Her-Dxd.
- the test ADCs of the invention (except for Her3-1) were observed with an EC 50 of 0.5 ⁇ 0.7 nM, while 0.6 for Her-Dxd.
- the ADCs of the invention featuring the linkers and the linker-payloads of the invention, provided at least comparable or even better binding affinity compared with trastuzumab deruxtecan.
- Tumor cell lines purchased from ATCC
- NCI-N87, HCC1954, MDA-MB-231 and JIMT-1 cells were routinely cultured in RPMI1640 medium or DMEM medium.
- the day before the assay day cells were seeded into 96-well plates in the culture medium at appropriate cell densities.
- ADCs were serially diluted in the culture medium and added to each well.
- Her-Dxd prepared as described in Example 2 was used as the reference ADC and positive control.
- the buffer to dissolve ADCs was used as the negative control.
- the plates were then kept at 37°C and 5%CO 2 in incubator. After 4-6 days, cell viability was tested using CellTiter-Glo (Promega) .
- the IC 50 values were calculated using GraphPad Prism software.
- results are shown in FIG. 12. While neither the test ADCs of the invention nor Her-Dxd were observed with active cytotoxicity on JIMT-1 and MDA-MB-231 cells (IC 50 >1nM) , in N87 and HCC1954 cells, all the test ADCs of the invention showed cytotoxicity comparable to the native ADC, with IC 50 being around 0.1 nM. As seen, the ADCs of the invention, featuring the linkers and the linker-payloads of the invention, provided at least comparable cytotoxicity as compared to trastuzumab deruxtecan.
Abstract
Provided are a linker, and linker-payloads and ADCs comprising same.
Description
The present invention relates to the field of drug conjugates, and more particularly, antibody-drug conjugates.
Antibody-drug conjugates (ADCs) refer to a group of macromolecular drugs that utilize specific binding of antibodies toward antigens (on the surface of cancer cells) to bring cytotoxic agents (drugs) to cells to kill them. They can be considered both a site-directed and site-specifically released macromolecular pro-drug. An ADC is essentially a three component system comprising a potent drug substance linked via a degradable or non-degradable (cleavable/non-cleavable) linker to an antibody, usually monoclonal antibody mAb.
Upon binding to the antigen on a cell, an ADC usually is internalized, and then under the intracellular conditions, the drug is released from the antibody to take effects. Comparing to small molecules, number of ADC molecules reaching target cells are smaller, and internalization rate is also slower. Therefore a quick cleavage of the linker to release drug is desirable.
A linker plays a very important role in an ADC, such as in terms of ADC stability and drug release mechanism. An enzyme-assisted cleavable linker, such as the one in Trastuzumab deruxtecanusually comprises a short peptide (e.g., 2~4 amino acids) that is cleaved in lysosome once the ADC is internalized, allowing drug to be released for its cell-killing effects. How fast the linker is cleaved by an enzyme (or enzymes) thus determines how fast the drug takes effects in an already-slow ADC mechanism of action. Cleavable linkers are used in most ADCs to date due to their ability of quick release of drugs in target cells. For example, brentuximab vedotin trastuzumab deruxtecan loncastuximab tesirine-lpyl all use peptidyl cleavage fragments, VC, GGFG, VA, respectively. These peptides are cleaved mainly by enzymes of the cathepsin family (cathepsin B mainly) in lysosome. The rates of cleavage vary, depending on multiple factors, including the nature of enzymes involved, the region-specification enzyme-substrate interaction, etc. For example, the linker of Trastuzumab deruxtecan contains a tetrapeptide GGFG, wherein the amide bond of the last amino acid glycine serves as the scissile bond for cleavage by lysosomal protease (e.g., cathepsin family) . The rate of cleavage in the case of GGFG is not as fast as in VC.
Fast cleavage of the linker at a desired site, e.g. in lysosome, is a desirable character for ADCs. There exists the need for linkers and linker-payloads that allow for providing ADC products with improved properties and manufacturing ADCs via a process with improved operability and productivity.
The inventors designed a series of linkers, which are suitable for producing linker-payloads and ADCs with improved properties, such as increased cleavability (e.g., as demonstrated by an improved rate of cleavage) , DAR distribution, homogeneity, stability and/or therapeutically relevant efficacy. The linkers and the linker-payloads comprising same allow for manufacturing ADCs via a process with improved operability and productivity, such as provision of cleaner ADC products with decreased level of leftover un-conjugated linker-payloads and/or easier removal of the leftover linker-payloads.
In a first aspect, provided herein is a compound of formula I:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof;
wherein, ″*″ indicates a chiral center, which is S-or R-or racemic; and the hydrogen atom attached to the chiral carbon atom and the hydrogen atom attached to the carbon atom with a R2 substituent are omitted from the formula;
L1 is - (CH2) a-, wherein a is an integer from 0 to 10, or - (CH2CH2O) b-, wherein b is an integer from 1 to 36;
L2 is - (CH2) c-, wherein c is an integer from 1 to 10, or - (CH2CH2O) d-, wherein d is an integer from 1 to 36;
L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 10, or - (CH2CH2O) f-, wherein f is an integer from 1 to 36;
R1 is -CF3, -NRaRb, -NRa (C=O) Rb, or -O (CH2) gCH3, wherein g is an integer from 0 to 3, Ra is H, or -C1-6 alkyl, Rb is H or -C1-6 alkyl;
R2 is -H, -C1-6 alkyl, or -O (CH2) hCH3, wherein h is an integer from 0 to 3;
X is halo, -OR3 or -NR4R5;
R3 is -H, -C1-6 alkyl or halo;
R4 and R5 are independently -H or -C1-6 alkyl;
n= 0 or 1; and
m= 0 or 1.
In a further aspect, provided herein is a conjugate compound of formula II:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof; wherein, ″*″ , L1, L2, L3, R1, R2, n and m are define as in formula I; and ″DRUG″ is a drug moiety covalently conjugated to the linker moiety.
In a further aspect, provided herein is an antibody-drug conjugate of formula III:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof; wherein, ″*″ , L1, L2, L3, R1, R2, n and m and ″DRUG″ are define as in formula II, and p is 1 to 8, such as 1, 2, 3, 4, 5, 6, 7 and 8; Ab refers to an antibody.
In a further aspect, provided herein is a method of producing a linker-payload compound, comprising conjugating a drug with a linker compound of the invention. In some embodiments, the drug is exatecan.
In a further aspect, provided herein is a method of producing an antibody-drug-conjugate, comprising
(a) conjugating a drug with the linker compound of the invention to obtain a linker-payload compound; wherein, preferably, the drug is exatecan; and
(b) conjugating an antibody with the linker-payload compound obtained in step (a) .
Brief Description of the Figures
Figure 1: A scheme of synthesizing linker-payload compound (also referred to as ″Deruxtecan analog″ in the figures) 1-7 according to a representative example of the invention.
Figure 2: A scheme of synthesizing linker-payload compound 3-1 according to another representative example of the invention.
Figure 3: A scheme of synthesizing linker-payload compound 1-1 according to another representative example of the invention.
Figure 4: A scheme of synthesizing linker-payload compound 1-2 according to another
representative example of the invention.
Figure 5: A scheme of synthesizing linker-payload compound 1-3 according to another representative example of the invention.
Figure 6: A scheme of synthesizing linker-payload compound 1-4 according to another representative example of the invention.
Figure 7: A scheme of synthesizing linker-payload compound 1-8 according to another representative example of the invention.
Figure 8: A scheme of synthesizing linker-payload compound 3-4 according to another representative example of the invention.
Figure 9: (a) A schematic depiction of the site of modification (circled) and the site of cleavage (dash line) in a linker-payload compound of the invention in comparison with the native linker payload; and (b) percentage (%) of cleavage over time for the linker-payload of the invention in comparison with the native liker-payload.
Figure 10: (a) A schematic depiction of the site of modification (circled) and the site of cleavage (dash line) in an ADC comprising a linker-payload moiety of the invention in comparison with an ADC comprising the native linker payload moiety; and (b) percentage (%) of cleavage over time for the linker-payload moiety of the invention in ADC in comparison with cleavage of the native liker-payload moiety in ADC.
Figure 11: Binding affinity of ADCs comprising different linker-payload moieties to antigen Her2 on different cell lines.
Figure 12: Cytotoxicity of ADCs comprising different linker-payload moieties on different cell lines.
Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from the detailed description.
Nomenclature and Definitions
As used herein, singular forms preceded by “a” , “an” and “the” include plural reference unless the context clearly dictates otherwise. As well, the terms “a” (or “an” ) , “one or more” and “at least one” can be used interchangeably herein.
In the present disclosure, unless otherwise specified, a value or value range, with or without being preceded by the term “about” or “approximately” covers equivalents within a reasonable
range of approximation as can be understood by an artisan in the related field, such as a range of ±10%, ±5%, ±3%, ±2%, ±1%or ±0.5%around the specified value.
As used herein, the terms ″substantially no″ and ″substantially free (of) ″ with regard to presence of a scenario or a substance not only refers to absence (i.e., ″no″ , ″zero″ or ″free (of) ″ ) but also refers to a presence of insignificance or a presence or an amount below the limit of an assay and thus undetectable. This can be well understood by a skilled person in the art.
One or more features in one embodiment can be combined with any one or more features in another embodiment according to the present disclosure without departing from the spirit and concept of the present invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skills in the fields to which this invention pertains. All publications and patents specifically mentioned herein are incorporated by reference for all purposes. All references cited herein are to be taken as indicative of the level of the skill in the art, which should not be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
General
The cleavage rate of peptide linkers depends on multiple factors, such as the nature of enzymes as involved, region-specific enzyme-substrate interaction, etc. We designed a series of linkers based on the finding that by altering the structures flanking the tetrapeptide GGFG, enzyme binding properties of the linker can be altered, as demonstrated by an increase in the kcat/Km value of cathapsin B. Using these linkers, linker-payload compounds and ADCs with improved properties and performance can be obtained. As shown in the described examples herein below, linker-payloads of the invention comprising the designed linker moieties exhibited increased cathepsin B cleavage rate, either as a solitary compound or a moiety in an ADC, compared to a reference comprising an analogous existing linker moiety. It was observed that the designed linkers are more prone to enzyme cleavage, which helps to improve efficacy of ADCs. Further, it was observed that ADCs comprising the linker-payload moieties of the invention may exhibit an increased stability (e.g., storage stability, such as freeze-thaw stability) and/or a comparable or even better therapeutically relevant efficacy (e.g., binding affinity and/or cytotoxicity) as compared to an existing analogous ADC.
At the same time we observed that ADC manufacturing using linker-payloads of the invention comprising the designed linker moieties can provide a cleaner product, for example, as compared with at a high drug-antibody ratio (DAR) . DAR of is 7.5. For higher DAR, more linker-payload is needed in the conjugation reaction. As a result, removal of the leftover linker-payloads can be onerous. In the present invention, the linker-payloads of the invention can
be more easily and completely removed, for example, as compared to deruxtecan in Enhertu, and thereby can yield cleaner ADC products. This might be explained by increased hydrophilicity of the linker-payloads of the invention. Meanwhile, when large excess of linker-payload is used in conjugation to achieve a high DAR, nonspecific loading of linker-payloads onto the heavy chains of the antibody can occur, which forms 4-drug-conjugated heavy chains, while ideally the maximal number is 3. In the present invention, percentage of 4-drug-conjugated heavy chain can be decreased to as low as 1/3 of that in the case ofAccordingly, linkers and linker-payloads of the present invention can provide ADC products with improved homogeneity.
Further, we observed that ADCs prepared using the linker-payloads of the invention can be more easily purified. In some cases, after purification via UFDF (Ultra Filtration &Deep Filtration) , the free linker-payloads left in the ADC products after conjugation are significantly decreased, for example, as compared to products produced using the linker-payload used in Accordingly, the linkers and the linker-payloads of the present invention allow for producing ADCs with improved purity, and also allow for manufacturing ADCs via a process with improved operability and productivity.
Exemplary Embodiments of the Invention
1. Linker
In the present disclosure, the term ″linker″ , as can be understood from the context, may refer to either a solitary linker compound of the invention or a linker moiety as incorporated into and thus as part of a linker-payload conjugate or an antibody-drug conjugate according to the present invention. As can be understood, a linker moiety refers to the moiety derived from the corresponding linker compound when being incorporated in the conjugates via conjugation.
In one aspect, the present invention provides a linker compound having the structure of formula I:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof;
wherein, ″*″ indicates a chiral center, which is S-or R-or racemic; and the hydrogen atom attached to the chiral carbon atom and the hydrogen atom attached to the carbon atom with a R2 substituent are omitted from the formula;
L1 is - (CH2) a-, wherein a is an integer from 0 to10, preferably from 1 to 8, more preferably from 2 to 6 or from 4 to 5, or - (CH2CH2O) b-, wherein b is an integer from 1 to 36, preferably from 2 to 30, more preferably from 3 to 25 or from 4 to 20;
L2 is - (CH2) c-, wherein c is an integer from 1 to 10, preferably from 1 to 8 or 1 to 6, more preferably, from 1 to 2; or - (CH2CH2O) d-, wherein d is an integer from 1 to 36, preferably from 2 to 30, more preferably from 3 to 25 or from 4 to 20;
L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 10, preferably from 1 to 8 or 1 to 6, more preferably from 1 to 2, or - (CH2CH2O) f-, wherein f is an integer from 1 to 36 preferably from 1 to 20, more preferably from 1 to 2, from 3 to 25 or from 4 to 20;
R1 is -CF3, -NRaRb, -NRa (C=O) Rb, or -O (CH2) gCH3, wherein g is an integer from 0 to 3, preferably from 1 to 2, Ra is H, or -C1-6 alkyl, preferably is -H, or -CH3; Rb is H or -C1-6 alkyl, preferably is -H, or -CH3; preferably R1 is -CF3, -N (CH3) 2, -NH (C=O) CH3, or -O (CH2) 2CH3;
R2 is -H, -C1-6 alkyl, or -O (CH2) hCH3, wherein h is an integer from 0 to 3, preferably R2 is -H or -CH3;
X is halo, -OR3 or -NR4R5, preferably -OR3;
R3 is -H, -C1-6 alkyl or halo, preferably -H, -CH3, t-butyl or Cl;
R4 and R5 are independently -H or -C1-6 alkyl;
n= 0 or 1; and
m= 0 or 1.
Specific examples of the linker compounds include Compounds L-1-1, L-1-2, L-1-3, L-1-4, L-1-7, L-1-8, L-3-1 and L-3-4 as shown below, or a pharmaceutically acceptable salt or ester thereof:
wherein ″*″ indicates a chiral center, which is racemic.
The designed linkers provide unique features and chemical properties. For example, in L-1-1, L-1-2, L-1-3, L-1-4, L-1-7, and L-1-8, a CF3 group is introduced to the alpha position of an amine residue to generate a strong dipolar moiety at the N-side of the GGFG peptide. This group most likely reduces Km of cathepsin B-GGFG interaction and thus accelerates the enzymatic catalysis rate of the hydrolysis of the peptide. Apparently, introduction of tetra-amine or acetyl amine at the similar position of the linker (e.g., as in L-3-1 and L-3-4) also leads to the catalytic rate increase.
We further explored modifications on the N-side of the tetrapeptide GGFG. We find that introduction of an extra methyl/methylene group (e.g., as in L-1-2, L-1-3, L-1-8) or ethyleneglycol group (e.g., as in L-1-7 and L-1-8) near the linkage to the drug moiety (e.g., exatecan or Dxd) resulted no compromise of cathepsin B cleavage rate.
2. Linker-payload
2.1. Linker-payload conjugates of the invention
In the present disclosure, the term ″linker-payload″ (also referred to as ″LP″ for short herein below) , as can be understood from the context, may refer to either a solitary linker-payload compound of the invention or a linker-payload moiety as incorporated into and thus as part of an antibody-drug conjugate according to the present invention. A linker-payload moiety may share the same numeral code with the corresponding linker-payload compound from which it derives via conjugation.
In the present disclosure, the term ″linker-payload compound″ refers to a conjugate compound composed of a linker moiety covalently conjugated to a drug moiety, wherein the drug moiety is also known as ″payload″ . The linker-payload compound may further be conjugated to an antibody to thereby provide an ADC comprising the linker-payload moiety of the invention.
Accordingly, in one aspect, the present invention provides a linker-payload conjugate having the structure of formula II:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof; wherein, ″*″ , L1, L2, L3, R1, R2, n and m are define as in formula I; and ″DRUG″ is a drug moiety covalently conjugated to the linker moiety.
In certain embodiments, the linker-payload conjugate may be a compound having any one of the following formulae, or a pharmaceutically acceptable salt or ester thereof:
wherein ″*″ indicates a chiral center, which is racemic.
The Drug useful in the present invention is not particularly limited, as long as it possesses or can be modified to possess a functionality group for conjugation with the linker compound at the end opposite to the maleimide moiety. In some embodiments, the functionality group for conjugation may be -NHR, wherein R is an alkyl or H.
As used herein, the term ″drug″ , as can be understood from the context, may refer to either a drug that forms the drug moiety covalently conjugated to the linker moiety in a linkier-payload compound or an ADC, or a drug that is released from a linker-payload or an ADC via enzymatic cleavage.
Drugs useful in the present invention include cytotoxic drugs, particularly those used in cancer therapy. Such drugs include, but are not limited to, DNA damaging agents, DNA binding agents, nucleic acid synthesis inhibitors, transcription inhibitors, anti-metabolites, enzyme inhibitors such as thymidylate synthase inhibitors and topoisomerase inhibitors, tubulin inhibitors and toxins such as toxins of a bacterial, fungal, plant or animal origin. Specific examples include, for example, taxol, methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin, doxorubicin, mitomycin C, mitomycin A, caminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vinblastine, vincristine, vindesine, taxanes including taxol, taxotere retinoic acid, butyric acid, N8-acetyl spermidine, camptothecin, calicheamicin, esperamicin, ene-diynes, duocarmycin A, duocarmycin SA, calicheamicin, camptothecin, hemiasterlins, maytansinoids (including DM1, DM2, DM3, DM4) , auristatins including monomethylauristatin E (MMAE) , monomethylauristatin F (MMAF) and monomethylauristatin D (MMAD) , camptothecin, irinotecan, topotecan, exatecan, etoposide and derivatives thereof. In some embodiments, the drug is topoisomerase inhibitor, such as camptothecin, irinotecan, topotecan, exatecan, etoposide and derivatives thereof, like hodroxycamptothecin and Dxd. In some embodiments, the drug is Dxd. In some other embodiments, the drug is exatecan. In some embodiments, the drug is Dxd, when being released from the linker-payload or the ADC. In some other embodiments, the drug is exatecan, when being conjugated with the linker to form the drug moiety.
Correspondingly, the linker-payload conjugate may be a compound having the structure of formulae IIa, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof:
Wherein, ″*″ , L1, L2, L3, R1, R2, n and m are define as in formula II.
In some specific examples, the linker-payload conjugate may be a compound selected from the group consisting of Compounds 1-1, 1-2, 1-3, 1-4, 1-7, 1-8, 3-1 or 3-4 as shown below, or a pharmaceutically acceptable salt or ester thereof:
wherein ″*″ indicates a chiral center, which is racemic.
2.2. Synthesis of linker-payload conjugates
In an aspect of the invention, provided herein is a method of producing a linker-payload conjugate compound, comprising conjugating a drug with a linker compound of the invention. In some embodiments, the drug is exatecan.
Conjugating a drug with a linker compound can be carried out via a coupling reation (e.g., esterification reaction or amidation reaction) or interesterification reaction as known in the art, depending on the type of the functional group (s) at the terminal end of the linker compound and the type of the functional group (s) on the drug.
3. Antibody-Drug Conjugate
3.1. The antibody-drug conjugates of the invention
In one aspect, the present invention provides an antibody-drug conjugate comprising an antibody conjugated with one or more drug molecules via a linker moiety of the invention, which may be represented by formula III:
wherein ″*″ indicates a chiral center, which is racemic,
wherein p is 1 to 8, such as 1, 2, 3, 4, 5, 6, 7 and 8; in some embodiments, p is 2, 4 or 6; and in some embodiments, p is 4.
Basically, there are no limits on the antibodies that are usable in the present inbention. The antibody can be of any specificity, configuration and origins. In some embodiments, the antibody specifically binds to a tumor antigen (TA) , such as a tumor specific antigen (TSA) and a tumor-associated antigen (TAA) . Examples of the tumor antigen include, but are not limited to, CD20, CD38, CD123, ROR1, ROR2, BCMA, PSMA, SSTR2, SSTR5, CD19, FLT3, CD33, PSCA, ADAM 17, CEA, Her2, EGFR, EGFR-vIII, CD30, FOLR1, GD-2, CA-IX, Trop2, CD70, CD38, mesothelin, EphA2, CD22, CD79b, GPNMB, CD56, CD138, CD52, CD74, CD30, CD123, RON, and ERBB2. Examples of TA-specific antibodies include, but are not limited to, Trastuzumab, Rituximab, Cetuximab, Bevacizumab, Panitumumab, Alemtuzumab, Matuzumab, Gemtuzumab, Polatuzumab, Inotuzumab, etc. In some embodiments, the antibody (Ab) is Trastuzumab.
In context of the ADC according to the invention, the term ″antibody″ includes fragments of
antibody, such as Fab fragments, Fab′ fragments, F (ab′) 2 fragments, Fv fragments and scFv fragments. Further, the term ″antibody″ may extend to include functional equivalents such as ligands and binding proteins that specifically recognize and bind to a target molecule such as an antigen (e.g., tumor antigens) , a receptor or other surface molecules on a targeted cell, such as pathology-associated cells, like cancer or tumor cells, as long as the equivalent molecule possesses or can be modified to possess a functionality group that can react with the maleimide moiety of the linker and thereby covalently binding to the linker. In some embodiments, the functionality group is a thiol group, such as those released via reduction of inter-chain disulfides, so that the antibody can be conjugated to the linker moiety via a thio-maleimide linkage.
3.2. Preparation of antibody-drug conjugates
In an aspect, the present invention provides a method of producing an antibody-drug-conjugate, comprising conjugating an antibody with a linker-payload compound of the invention.
In some embodiments, the method may comprises:
(a) conjugating a drug with a linker compound of the invention to obtain a linker-payload compound; preferably, the drug is exatecan; and
(b) conjugating an antibody with a linker-payload compound obtained in step (a) .
Step (a) can be carried out via a coupling reation (e.g., esterification reaction or amidation reaction) or interesterification reaction as known in the art, depending on the type of the functional group (s) at the terminal end of the linker compound and the type of the functional group (s) on the drug.
Step (b) can be carried out by reacting a maleimido moiety with a free thiol group from the antibody via Michael addition reaction. For example, the free thiol group (s) may come from the cysteine residue (s) , such as those released by reduction of an inter-chain disulfide bond, so that the antibody can be conjugated to the linker moiety via a thio-maleimide linkage.
4. Applications
The antibody-drug-conjugate of the invention can be formulated with a pharmaceutically acceptable excipient to provide a pharmaceutical composition. In some embodiments, the composition may comprise a therapeutically effective amount of the antibody-drug-conjugate. In some embodiments, the composition may comprise an effective amount of the antibody-drug-conjugate that allows for obtaining a dosage as desired.
The antibody-drug conjugate of the invention can be used for treating a disease, disorder or condition in a subject in need thereof, wherein the treatment may comprise administrating to the subject a therapeutically effective amount of the antibody drug-conjugate. Also provided herein is an antibody-drug conjugate according to the present invention for use in treatment of a disease,
disorder or condition in a subject in need thereof. The disease to be treated may include but are not be limited to cancers, including solid tumors and hematopoeitic malignancies. Examples of such cancers include but are not limited to breast cancers, gastric cancers, pancreatic cancers, hepatic cancers, lung cancers (e.g., NSCLC) , head and neck cancers, colorectal cancers, B cell lymphomas (e.g., non-Hodgkin’s lymphoma (NHL) ) and leukemia.
As used herein, the term “subject” refers to a human or a non-human animal subject. Non-human animals may be mammals, such as primates. Examples of non-human animal subjects include but are not limited to domestic animals, farm animals, and zoo, sports, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, swine, cows, and bears. Preferably, the subject is a human. A ″subject in need thereof″ refers to a subject in need of diagnosis, prognosis, amelioration, prevention and/or treatment of a disease, disorder or condition.
Examples
The following Examples are provided merely for illustration, with no intent to limit scope of the invention.
Example 1: Synthesis of Linker-payloads
(a) Synthesis of Compound 1-7 (also called Deruxtecan analog 1-7 in FIG. 1)
The process of synthesis is schematically depicted in FIG. 1.
Step 1: methyl 2- (2- ( (tert-butyldimethylsilyl) oxy) ethoxy) acetate (a-1)
To a stirred solution of 2- ( (tert-butyldimethylsilyl) oxy) ethanol (6.51 g, 42.5 mmol) in anhydrous tert-butanol (50.0 mL) was added potassium tert-butoxide (3.18 g, 28.3 mmol) and stirred at 0 ℃ for 1 hr. And then methyl 2-bromoacetate (5.00 g, 28.3 mmol) in tert-butanol (50.0 mL) was added dropwise, the resulting solution was allowed to warm to 0 -25 ℃ and stirred for 2 hrs. TLC (Petroleum ether /Ethyl acetate = 10: 1, Rf = 0.2) showed the reaction was complete. The reaction mixture was quenched by addition of water (100 mL) at 0℃, and extracted with dichloromethane 50.0 mL (50.0 mL *3) . The combined organic layers were washed with brine (20.0 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silica gel, Petroleum ether/Ethyl acetate = 50/1 to 2/1) to give methyl 2- (2- ( (tert-butyldimethylsilyl) oxy) ethoxy) acetate (3.00 g, 42.5%yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) : δ ppm 4.19 (s, 2 H) , 3.79 -3.84 (m, 2 H) , 3.76 (s, 2 H) , 3.62 -3.67 (m, 2 H) , 0.90 (s, 9 H) , 0.07 (s, 6 H) .
Step 2: benzyl 2- (2-hydroxyethoxy) acetate (a-2)
To a solution of methyl 2- (2- ( (tert-butyldimethylsilyl) oxy) ethoxy) acetate, a-1 (800 mg, 4.03 mmol) in mixture of tetrahydrofuran (10.0 mL) and water (10.0 mL) was added lithium hydroxide monohydrate (168 mg, 4.03 mmol) . The mixture was stirred at 25 ℃ for 2 hrs. TLC (Petroleum
ether /Ethyl acetate = 5: 1, Rf = 0.2) showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to remove water and tetrahydrofuran to give a residue. The residue was dissolve in N, N-Dimethylformamide (5.00 mL) and added potassium carbonate (556 mg, 4.03 mmol) and benzyl bromide (1.38 g, 8.05 mmol) , the mixture was stirred at 25 ℃ for 16 hrs. TLC (Petroleum ether /Ethyl acetate = 10: 1, Rf = 0.5) indicated intermediate was consumed completely, the reaction was messy according to TLC. The reaction mixture was concentrated under reduced pressure to remove N, N-Dimethylformamide and purified by column chromatography (SiO2, Petroleum ether /Ethyl acetate=100/1 to 50/1) to give intermediate (1.30 g) as light yellow liquid. The intermediate was de-TBS at 1 M HCl (5.00 mL) . TLC (Petroleum ether /Ethyl acetate = 2: 1, Rf = 0.5) indicated intermediate was consumed completely, the reaction was messy according to TLC. The reaction mixture was purified by column chromatography (silica gel, Petroleum ether /Ethyl acetate=50/1 to 2/1) to give benzyl 2- (2-hydroxyethoxy) acetate (600 mg, 88.6%yield) as light yellow liquid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.28 -7.41 (m, 5 H) , 5.20 (s, 2 H) , 4.22 (s, 2 H) , 3.81 (t, g= 5.1 Hz, 3 H) , 3.64 -3.68 (m, 2 H) , 0.90 (s, 9 H) , 0.07 (s, 6 H) .
Step 3: benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate (a-4)
To a mixture of benzyl 2- (2-hydroxyethoxy) acetate, a-2 (400 mg, 1.09 mmol) and (2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) acetamido) methyl acetate a-3 (342 mg, 1.63 mmol) in tetrahydrofuran (4.00 mL) was added 4-methylbenzenesulfonic acid monohydrate (10.4 mg, 54.2 umol) , then the mixture was stirred at 25 ℃ for 1 hr. TLC (Petroleum ether /Ethyl acetate = 1: 1, Rf = 0.2) showed the reaction was complete. The mixture was diluted with sodium hydrogen carbonate (10.0 mL) and extracted with ethyl acetate (30.0 mL) . The combined organic layers were dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (100-200 mesh silica gel) eluted with (Petroleum ether /Ethyl acetate =50/1 to 1/1) to give benzyl 1- (9H-fluoren-9-yl) -3,6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate (0.40 g, 71.0 %yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.77 (d, g= 7.5 Hz, 2 H) , 7.61 (d, g= 7.5 Hz, 2 H) , 7.30 -7.44 (m, 9 H) , 5.13 -5.22 (m, 2 H) , 4.81 (d, g= 6.8 Hz, 2 H) , 4.44 (d, g= 6.8 Hz, 2 H) , 4.15 -4.18 (m, 2 H) , 3.92 (d, g= 5.5 Hz, 2 H) , 3.73 -3.76 (m, 2 H) , 3.68 (d, g= 2.5 Hz, 2 H) .
Step 4: 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oic acid (a-5)
To a mixture of benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate, a-4 (0.40 g, 771 umol) in ethanol (20.0 mL) and ethyl acetate (20.0 mL) was added dry Pd/C (0.80 g) , under hydrogen atmosphere (15 psi) stirred at 25 ℃ for 3 hrs. TLC (DCM/MeOH= 10: 1, Rf = 0.3) showed the reaction was complete. The reaction mixture was fileted through siliceous earth, and the filtrate was concentrated under reduced pressure to give 1- (9H-fluoren-9-yl) -3, 6-
dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oic acid (0.25 g, 75.6 %yield) as a colorless oil. The crude product was used for next step directly without purification. 1H NMR (400 MHz, CDCl3) : δ ppm 8.64 -8.74 (m, 1 H) , 7.83 -7.95 (m, 2 H) , 7.73 (d, g= 7.4 Hz, 1 H) , 7.55 -7.62 (m, 1 H) , 7.26 -7.49 (m, 4 H) , 4.56 (d, g= 6.5 Hz, 2 H) , 4.26 -4.35 (m, 2 H) , 3.64 (d, g= 4.4 Hz, 2 H) , 3.49 -3.60 (m, 4 H) .
Step 5: (a-6, i.e., L-1-7)
To a mixture containing CTC-Resin (0.50 g, 14.1 mmol) and 1- (9H-fluoren-9-yl) -3, 6-dioxo-2,9, 12-trioxa-4, 7-diazatetradecan-14-oic acid, a-5 (0.20 g, 520 umol) , N, N-diisopropylethylamine (0.25 g, 1.95 mmol) , dichloromethane (10.0 mL) was added into swell. The resin was mixed for 2 hrs, then added with methanol (5.00 mL) and mixed for 30 mins. And then, the resin was washed with N, N-Dimethylformamide (10.0 mL) for 3 times. The resin was treated with 20%piperidine in N, N-Dimethylformamide for 30 mins for Fmoc deprotection. The resin was washed with N, N-Dimethylformamide for 5 times. Then Fmoc-Phe-OH (0.58g, 1.31 mmol) was added and mixed for 30 secs, then O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate (HBTU) (0.54 g, 1.43 mmol) and N, N-diisopropylethylamine (0.25 g, 1.95 mmol) in N, N-Dimethylformamide were added, and bubbled by nitrogen for 30 mins. The resin was washed with N,N-Dimethylformamide for 3 times. The above step was repeated for next amino acid Fmoc-Gly-OH (0.53 g, 1.50 mmol) and 2- ( (7- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -1, 1, 1-trifluoroheptan-2-yl) amino) acetic acid (0.20 g, 1.31 mmol) coupling at 25℃. The reaction was detected by ninhydrin test. The coupling reaction was monitored by ninhydrin color reaction. After washing with methanol 10.0 mL and drying under vacuum, 20.0 mL of cleavage buffer (20%HFIP/80%DCM) was added to the flask containing the resin of peptide, stirred for 2 mins for 2 times. The HFIP-mixture was removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H2O/CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give compound, a-6 (100 mg, crude, 90.0%purity) as a white solid. LCMS (ESI, m/z) : 713.68 [M+H] +: 715 (Xbrige C18, 3.5 um, 2.1 *30 mm column, Wavelength: UV 220 nm &254 nm;Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (10-80_2 min) . HPLC (Gemini-NX C18 5um 110A 150 *4.6mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (10-80_20 min)
Step 6: (Compound 1-7)
To a mixture of compound a-6 (59.7 mg, 79.2 umol, ) and 1-hydroxybenzotriazole (HOBt) (2.80 mg, 20.6 umol, ) in N, N-Dimethylformamide (1.00 mL) was added Exatecan mesylate (10.0 mg, 18.8 umol) and N, N-diisopropylcarbondiimide (DIC) (9.50 mg, 75.24 umol) , then the mixture was stirred at 40 ℃ for 2 hrs. TLC (DCM/MeOH = 10/1, Rf = 0.4) showed the reaction was complete. Traces of N, N-Dimethylformamide were removed in vacuum to give a residue. The
residue was purified by Flash (Eluent of 10-50%water/acetonitrile on C-18 column chromatography) . Then the resulting product was freeze-dried to give Compound 1-7 (8.00 mg, 37.4%yield, 95.7%purity) as a light yellow solid. LCMS (ESI, m/z) : 1131.1 [M+H] +: 1132.6 (Xbrige C18, 3.5 um, 2.1 *30 mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (10-80_2 min) . HPLC (Gemini-NX C18 5um 110A 150 *4.6mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (35-65_20+3 min) .
(b) Synthesis of Compound 3-1 (also called Deruxtecan analog 3-1 in in FIG. 2)
The process of synthesis is schematically depicted in FIG. 2.
Step 1: benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate (b-3)
To a mixture of (2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) acetamido) methyl acetate (500 mg, 1.36 mmol) and benzyl 3-hydroxypropanoate (366 mg, 2.04 mmol) in tetrahydrofuran (5.00 mL) was added 4-methylbenzenesulfonic acid monohydrate (12.9 mg, 67.8 umol) , then the mixture was stirred at 25 ℃ for 3 hrs. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. The mixture was diluted with saturation sodium bicarbonate (50.0 mL) and extracted with ethyl acetate (50.0 mL) . The combined organic layers were dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (100-200 mesh silica gel) eluted with (Petroleum ether/Ethyl acetate = 50/1 to 1/1) to give benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate, b-3 (400 mg, 60.3%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.90 (d, g=7.4 Hz, 2 H) , 7.73 (d, g=7.0 Hz, 2 H) , 7.24 -7.64 (m, 9 H) , 5.05 -5.14 (m, 2 H) , 4.48 -4.62 (m, 4 H) , 4.16 -4.34 (m, 3 H) , 3.54 -3.72 (m, 4 H) .
Step 2: 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid (a-3)
To a mixture of benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate (400 mg, 818 umol) in ethanol (10.0 mL) and ethyl acetate (10.0 mL) was added dry Pd/C (0.05 g) , then the reaction mixture was stirred at 25 ℃ under hydrogen atmosphere (15 psi) for 5 hrs. TLC (DCM/MeOH= 10: 1, Rf = 0.2) showed raw material was consumed and one new spot was formed. The reaction mixture was filted through siliceous earth, and the filtrate was concentrated under reduced pressure to give 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid, a-3 (300 mg, 91.9%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.90 (d, g=7.4 Hz, 2 H) , 7.73 (d, g=7.0 Hz, 2 H) , 7.24 -7.64 (m, 4 H) , 5.05 -5.14 (m, 2 H) , 4.48 -4.62 (m, 2 H) , 4.16 -4.34 (m, 3 H) , 3.54 -3.72 (m, 4 H) .
Step 3: (S) -2-amino-6- ( (tert-butoxycarbonyl) amino) hexanoic acid (b-6)
A solution of (S) -2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) -6- ( (tert-butoxycarbonyl)
amino) hexanoic acid (5.00 g, 10.67 mmol) in mixture of N, N-Dimethylformamide (10.0 mL) and triethylamine (2.50 mL) was stirred at 25 ℃ for 16 hrs. TLC (DCM: MeOH = 10: 1, Rf = 0.2) showed the reaction was complete. The reaction mixture was added drop-wise to a solution of stirring isopropyl ether (100 mL) and the resulting solid was filtered, and the solid was washed with isopropyl ether (50 mL) . Traces of isopropyl ether were removed in vacuum to give (S) -2-amino-6- ( (tert-butoxycarbonyl) amino) hexanoic acid, b-6 (2.50 g, 95.1%yield) as a white solid. The crude product was used into the next step without further purification. 1H NMR (400 MHz, CDCl3) : δ ppm 3.67 (t, g= 6.1 Hz, 1 H) , 3.03 (t, g= 6.7 Hz, 2 H) , 1.73 -1.90 (m, 2 H) , 1.23 -1.56 (m, 12 H) .
Step 4: (S) -6- ( (tert-butoxycarbonyl) amino) -2- (dimethylamino) hexanoic acid (b-7)
To a solution of (S) -2-amino-6- ( (tert-butoxycarbonyl) amino) hexanoic acid (2.00 g, 8.12 mmol) in trifluoroethanol (14.0 mL) was added dropwise with formaldehyde (1.32 g, 16.2 mmol, 37%purity) at 25 ℃ and stirred at this temperature for 30 mins, then sodium borohydride (614 mg, 16.2 mmol) was added dropwise over a period of 30 mins in the ice bath and then kept at 25 ℃ for another 30 mins. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. Traces of trifluoroethanol (14.0 mL) were removed in vacuum to give a residue and then diluted with 1%acetic acid (20.0 mL) . The mixture was purified by Flash (Eluent of 10~50%H2O (0.1%TFA /CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give (S) -6- ( (tert-butoxycarbonyl) amino) -2-(dimethylamino) hexanoic acid, b-7 (1.20 g, 53.8%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 3.16 (t, g= 7.0 Hz, 1 H) , 3.02 (t, g= 6.8 Hz, 2 H) , 2.52 (s, 6 H) , 1.66 -1.73 (m, 2 H) , 1.46 (ddd, g= 11.0, 7.0, 4.0 Hz, 2 H) , 1.38 (s, 9 H) , 1.22 -1.31 (m, 2 H) .
Step 5: (S) -2- (dimethylamino) -6- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) hexanoic acid (b-9)
A solution of (S) -6- ( (tert-butoxycarbonyl) amino) -2- (dimethylamino) hexanoic acid, b-7 (0.60 g, 2.19 mmol) in mixture of trifluoroacetic acid (0.60 mL) and dichloromethane (6.00 mL) , was stirred at 25 ℃ for 2 hrs. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to remove dichloromethane and trifluoroacetic acid to give de-Boc product as colorless oil. The colorless oil was dissolved in saturation sodium bicarbonate (6.00 mL) at 0 ℃, after, methyl 2, 5-dioxo-2, 5-dihydro-1H-pyrrole-1-carboxylate (407 mg, 2.62 mmol) was added to the reaction mixture and stirred for 0 ℃ at 1 hr and then kept at 25 ℃ for another 3 hrs. LC-MS showed intermediate was consumed completely and one main peak with desired mass was detected. The reaction mixture was acidized by addition 1 M HCl (5.00 mL) and purified by Flash (Eluent of 10~50%H2O (0.1%TFA) /CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give (S) -2- (dimethylamino) -6- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-
yl)hexanoic acid, b-9 (500 mg, 89.9%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 6.80 (s, 2 H) , 3.79 (dd, g= 8.5, 4.4 Hz, 1 H) , 3.49 (t, g= 6.8 Hz, 2 H) , 2.88 (d, g= 13.4 Hz, 6 H) , 1.89 -2.00 (m, 2 H) , 1.56 -1.64 (m, 2 H) , 1.30 -1.40 (m, 2 H) .
Step 6: (3S, 12S) -12-benzyl-3- (4- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) butyl) -2-methyl-4, 7, 10, 13, 16-pentaoxo-19-oxa-2, 5, 8, 11, 14, 17-hexaazadocosan-22-oic acid (b-10, i.e., L-3-1)
To a mixture containing CTC-Resin (0.50 g, 14.1 mmol) and 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid, a-3 (0.20 g, 520 umol) , N, N-diisopropylethylamine (DIEA) (0.25 g, 1.95 mmol) , dichloromethane (10.0 mL) were added into swell. The resin was mixed for 2 hrs, then added with methanol (5.00 mL) and mixed for 30 mins. And then, the resin was washed with N, N-Dimethylformamide (10.0 mL) for 3 times. The resin was treated with 20%piperidine in N, N-Dimethylformamide for 30 mins for Fmoc deprotection. The resin was washed with N, N-Dimethylformamide for 5 times. Then Fmoc-Phe-OH (0.58g, 1.31 mmol) was added and mixed for 30 secs, then O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate (HBTU) (0.54 g, 1.43 mmol) and N, N-diisopropylethylamine (DIEA) (0.25 g, 1.95 mmol) in N, N-Dimethylformamide were added and bubbled by N2 for 30 mins. The resin was washed with N, N-Dimethylformamide for 3 times. The above step was repeated for next amino acid Fmoc-Gly-Gly-OH (0.53 g, 1.50 mmol) and special amino acid (S) -2- (dimethylamino) -6- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) hexanoic acid, b-9 (0.20 g, 1.31 mmol) coupling at 25℃. The reaction was detected by ninhydrin test. The coupling reaction was monitored by ninhydrin color reaction. After washing with methanol 10.0 mL and drying under vacuum, 20.0 mL of cleavage buffer (20%HFIP/80%DCM) was added to the flask containing the resin of peptide, stirred for 2 mins for 2 times. The HFIP-mixture was removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H2O/CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give (3S, 12S) -12-benzyl-3- (4- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl)butyl) -2-methyl-4, 7, 10, 13, 16-pentaoxo-19-oxa-2, 5, 8, 11, 14, 17-hexaazadocosan-22-oic acid, b-10 (30.0 mg, 4.39%yield) as a white solid.
Step 7: Compound 3-1
To a mixture of (3S, 12S) -12-benzyl-3- (4- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) butyl) -2-methyl-4, 7, 10, 13, 16-pentaoxo-19-oxa-2, 5, 8, 11, 14, 17-hexaazadocosan-22-oic acid, b-10 (18.6 mg, 28.2 umol, ) and 1-hydroxybenzotriazole (HOBt) (2.80 mg, 20.6 umol, ) in N, N-Dimethylformamide (1.00 mL) was added Exatecan mesylate (10.0 mg, 18.8 umol) and N, N-diisopropylcarbondiimide (DIC) (9.50 mg, 75.24 umol) , then the mixture was stirred at 25 ℃ for 3 hrs. TLC (DCM: MeOH = 10: 1, Rf = 0.4) showed the reaction was complete. Traces of N, N-Dimethylformamide were removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H2O/CH3CN on C-18 column chromatography) . Then the resulting product
was freeze-dried to give compound 3-1 (7.20 mg, 35.4%yield) as a light yellow solid. LCMS (ESI, m/z) : 1077.1 [M+H] +: 1077.6 (Xbrige C18, 3.5 um, 2.1 *30 mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (10-80_2 min) . HPLC (Gemini-NX C18 5um 110A 150 *4.6mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water: 0.1%TFA in acetonitrile (25-55_20+3 min) .
(c) Synthesis of Other Compounds
Synthesis of compound 1-1 (also called Deruxtecan analog 1-1 in FIG. 3)
Step 1: 10-benzyl-23- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -6, 9, 12, 15-tetraoxo-18- (trifluoromethyl) -3-oxa-5, 8, 11, 14, 17-pentaazatricosan-1-oic acid (c-1, i.e., L-1-1)
Peptide Synthesis:
The peptide was synthesized using standard Fmoc chemistry.
1) Add DCM to the vessel containing CTC Resin (0.25 mmol, 0.44 g, Sub=0.57 mmol/g) and
5-benzyl-1- (9H-fluoren-9-yl) -3, 6, 9-trioxo-2, 12-dioxa-4, 7, 10-triazatetradecan-14-oic acid (0.10 g, 0.25 mmol, 1.0 eq) with N2 bubbling.
2) Add DIEA (6.0 eq) dropwise and mix for 2 hours.
3) Add MeOH (0.8 mL) and mix for 30 min.
4) Drain and wash with DMF for 5 times.
5) Add 20%piperidine/DMF and react on 30 min.
6) Drain and wash with DMF for 3 times.
7) Add Fmoc-amino acid solution and mix for 30 seconds, then add activation buffer, N2 bubbling for about 1 hour.
8) Repeat step 5 to 7 for next amino acid coupling.
Note:
20%piperidine in DMF was used for Fmoc deprotection for 30 min. The coupling reaction was monitored by ninhydrin test, and the resin was washed with DMF for 5 times.
Peptide Cleavage and Purification:
1) Cleavage buffer (20%HFIP /DCM) was added to the peptide Resin, stirring for 3 min for 3 times.
2) The DCM was concentrated under reduced pressure.
3) The peptide was dried in high vacuum for 2 hours.
4) The crude peptide was purified by Prep-HPLC (A: 0.075%TFA in H2O, B: ACN) to give compound c-1 (26.0 mg, 95.0%purity, 7.36%yield) .
Step 2: (Deruxtecan analog 1-1)
To a solution of compound c-1 (21.0 mg, 31.3 umol, 1 eq) and EXATECAN MESYLATE (16.6 mg, 31.3 umol) in DMF (0.5 mL) was added HOAt (12.8 mg, 93.9 umol, 3 eq) , DIC (15.8 mg, 125.2 umol, 4 eq) and DIEA (12.14 mg, 93.9 umol, 3 eq) , then the reaction mixture was stirred at 25 ℃ for 16 hrs. LCMS showed compound c-1 was consumed and one main peak with desired mass was detected. The reaction mixture was purified by prep-HPLC (natural condition, pure water) directly, two peaks with desired mass was detected in perp-HPLC, separated and lyophilized to obtained Deruxtecan analog 1-1 (Peak 1: 1.4 mg, 85.97%purity, Peak 2: 7.1 mg, 90.32%purity, 22.3%yield) as a white solid.
Synthesis of compound 1-2 (also called Deruxtecan analog 1-2 in FIG. 4)
Step 1: (S) -benzyl 1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oate (d-3)
To a mixture of (2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) acetamido) methyl acetate (5g, 13.57 mmol) and (S) -benzyl 2-hydroxypropanoate (d-2, 4.89 g, 27.15 mmol) in tetrahydrofuran (50.0 mL) was added 4-methylbenzenesulfonic acid hydrate (129.09 mg, 678.64 umol) , then the mixture was stirred at 25 ℃ for 5 hrs. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. The residue was purified by prep-HPLC (TFA condition) . Compound (S) -benzyl 1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2,9-dioxa-4, 7-diazaundecan-11-oate, d-3 (4.10 g, 8.38 mmol, 61.77%yield) was obtained as a yellow oil.
Step 2: (S) -1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oic
acid (d-4)
To a mixture of (S) -benzyl 1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oate, d-3 (2.00 g, 4.09 mmol) in tetrahydrofuran (20.0 mL) was added dry Pd/C (200 mg) , then the reaction mixture was stirred at 25 ℃ under hydrogen atmosphere (15 psi) for 4 hrs. TLC (DCM/MeOH= 10: 1, Rf = 0.3) showed raw material was consumed and one new spot was formed. The reaction mixture was fileted through siliceous earth, and the filtrate was concentrated under reduced pressure to give (S) -1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oic acid, d-4 (1.28 g, 3.21 mmol, 78.4%yield) as a white solid.
Step 3: (2S, 10S) -10-benzyl-23- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-6, 9, 12, 15-tetraoxo-18- (trifluoromethyl) -3-oxa-5, 8, 11, 14, 17-pentaazatricosan-1-oic acid (d-5, i.e., L-1-2)
To a mixture containing CTC-Resin (0.50 g, 0.50 mmol) and (S) -1- (9H-fluoren-9-yl) -10-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oic acid, d-4 (0.50 g, 500 umol) , N, N-diisopropylethylamine (DIEA) (2.00 mmol) , dichloromethane (10.0 mL) were added into swell. The resin was mixed for 2 hrs, then added with methanol (5.00 mL) and mixed for 30 mins. And then, the resin was washed with N, N-Dimethylformamide (10.0 mL) for 5 times. The resin was treated with 20%piperidine in N, N-Dimethylformamide for 30 mins for Fmoc deprotection. The resin was washed with N, N-Dimethylformamide for 3 times. Then Fmoc-Phe-OH (1.50 mmol) was added and mixed for 30 secs, then O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate (HBTU) (1.50 mmol) and N, N-diisopropylethylamine (DIEA) (3.00 mmol) in N, N-Dimethylformamide were added, and bubbled by N2 for 30 mins. The resin was washed with N, N-Dimethylformamide for 3 times. The above step was repeated for next amino acid Fmoc-Gly-OH (1.50 mmol) and special amino acid, 2- ( (7- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -1, 1, 1-trifluoroheptan-2-yl) amino) acetic acid (0.20 g, 1.31 mmol) coupling at 25℃. The reaction was detected by ninhydrin test. The coupling reaction was monitored by ninhydrin color reaction. After washing with methanol 10.0 mL and drying under vacuum, 20.0 mL of cleavage buffer (20%HFIP/80%DCM) was added to the flask containing the resin of peptide stirred for 2 mins for 2 times. The HFIP-mixture was removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H2O/CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give (2S, 10S) -10-benzyl-23- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-6, 9, 12, 15-tetraoxo-18- (trifluoromethyl) -3-oxa-5, 8, 11, 14, 17-pentaazatricosan-1-oic acid, d-5 (55.0 mg, 9.98%yield) as a white solid.
Step 4: (Deruxtecan analog 1-2)
To a mixture of (2S, 10S) -10-benzyl-23- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-
6,9, 12, 15-tetraoxo-18- (trifluoromethyl) -3-oxa-5, 8, 11, 14, 17-pentaazatricosan-1-oic acid, d-5 (20.0 mg, 29.2 umol) and 1-hydroxy-7-azabenzotriazole (HOAt) (7.95 mg, 58.4 umol) in N, N-Dimethylformamide (0.50 mL) was added Exatecan mesylate (15.5 mg, 29.2 umol) and N, N-diisopropylcarbondiimide (DIC) (22.1 mg, 175 umol, 27.1 uL) and N, N-diisopropylethylamine (DIEA) (7.55 mg, 58.4 umol, 10.1 uL, ) , then the mixture was stirred at 25 ℃ for 3 hrs. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. The reaction mixture was filtered to remove the undissolved residue. The residue was purified by prep-HPLC (TFA condition) . Then the resulting product was freeze-dried to give Deruxtecan analog 1-2 (18.8 mg, 17.0 umol, 58.4%yield, 96.3%purity) as a light yellow solid.
Synthesis of compound 1-3 (also called Deruxtecan analog 1-3 in FIG. 5)
Step 1: benzyl 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate (e-3)
To a mixture of compound a-3 (500 mg, 1.36 mmol) and compound e-2 (366 mg, 2.04 mmol) in THF (5.00 mL) was added 4-methylbenzenesulfonic acid monohydrate (12.9 mg, 67.8 umol) , then the mixture was stirred at 25 ℃ for 3 hrs. LC-MS showed compound a-3 was consumed completely and one main peak with desired mass was detected. The mixture was diluted with NaHCO3 (50.0 mL) and extracted with EtOAc (50.0 mL) . The combined organic layers were dried with Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (100-200 mesh silica gel) eluted with (Petroleum ether/Ethyl acetate = 50/1 to 1/1) to give compound e-3 (400 mg, 60.3%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.90 (d, J=7.4 Hz, 2 H) , 7.73 (d, J=7.0 Hz, 2 H) , 7.24 -7.64 (m, 9 H) , 5.05 -5.14 (m, 2 H) , 4.48 -4.62 (m, 4 H) , 4.16 -4.34 (m, 3 H) , 3.54 -3.72 (m, 4 H) .
Step 2: 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid (e-4)
To a mixture of compound e-3 (400 mg, 818 umol) in ethanol (10.0 mL) and ethyl acetate (10.0 mL) was added dry Pd/C (0.05 g) , then the reaction mixture was stirred at 25 ℃ under H2 atmosphere (15 psi) for 5 hrs. TLC (DCM/MeOH= 10: 1, Rf = 0.2) showed compound e-3 was consumed and one new spot was formed. The reaction mixture was fileted through siliceous earth, and the filtrate was concentrated under reduced pressure to give compound e-4 (300 mg, 91.9%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.90 (d, J=7.4 Hz, 2 H) , 7.73 (d, J=7.0 Hz, 2 H) , 7.24 -7.64 (m, 4 H) , 5.05 -5.14 (m, 2 H) , 4.48 -4.62 (m, 2 H) , 4.16 -4.34 (m, 3 H) , 3.54 -3.72 (m, 4 H) .
Step 3: (11S) -11-benzyl-24- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -7, 10, 13, 16-tetraoxo-19- (trifluoromethyl) -4-oxa-6, 9, 12, 15, 18-pentaazatetracosan-1-oic acid (e-5, i.e., L-1-3)
To a mixture containing CTC-Resin (0.50 g, 14.1 mmol) and compound e-4 (0.20 g, 520 umol) , DIEA (0.25 g, 1.95 mmol) , DCM (10.0 mL) were added into swell. The resin was mixed for 2 hrs, then MeOH (5.00 mL) was added and mixed for 30 mins. And then, the resin was washed with DMF (10.0 mL) for 3 times. The resin was treated with 20%piperidine in DMF for 30 min for Fmoc de-protection. The resin was washed with DMF for 5 times. Then Fmoc-Phe-OH (0.58g, 1.31 mmol) was added and mixed for 30 seconds, then HBTU (0.54 g, 1.43 mmol) and DIEA (0.25 g, 1.95 mmol) in DMF were added and bubbled by N2 for 30 mins. The resin was washed with DMF for 3 times. The above step was repeated for next amino acid Fmoc-Gly-OH (0.53 g, 1.50 mmol) and special amino acid, 2- ( (7- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -1, 1, 1-trifluoroheptan-2-yl) amino) acetic acid (0.20 g, 1.31 mmol) coupling at 25 ℃. The reaction was detected by ninhydrin test. The coupling reaction was monitored by ninhydrin color reaction. After washing with MeOH 10.0 mL and drying under vacuum, 20.0 mL of cleavage buffer (20%HFIP/80%DCM) was added to the flask containing the resin of peptide stirred for 2 mins for 2 times. The HFIP-mixture was removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H2O/CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give compound e-5 (30.0 mg, 4.39%yield) as a white solid.
Step 4: (Deruxtecan analog 1-3)
To a mixture of compound e-5 (27.2 mg, 37.6 umol, ) in DMF (1.00 mL) was added HATU (9.30 mg, 24.4 umol) , the reaction mixture was stirred at 25 ℃ for 20 mins. EXATECAN MESYLATE (10.0 mg, 18.8 umol) and DIEA (4.86 mg, 37.6 umol) were added to the reaction mixture and kept at 40 ℃ for 2 hrs. TLC (DCM: MeOH = 10: 1, Rf = 0.4) showed the reaction was complete. Traces of DMF were removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H2O/CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give Deruxtecan analog 1-3 (7.20 mg, 34.7%yield) as a light yellow solid.
Synthesis of compound 1-4 (also called Deruxtecan analog 1-4 in FIG. 6)
Step 1: (S) -methyl 1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate (f-3)
To a mixture of (2- ( ( ( (9H-fluoren-9-yl) methoxy) carbonyl) amino) acetamido) methyl acetate (5g, 13.5 mmol) and (S) -methyl 3-hydroxy-2-methylpropanoate (3.21 g, 27.1 mmol) in tetrahydrofuran (50.0 mL) was added 4-methylbenzenesulfonic acid hydrate (129 mg, 678 umol) , then the mixture was stirred at 25 ℃ for 1 hrs. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. The residue was purified by prep-
HPLC (TFA condition) . Compound (S) -methyl 1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate, f-3 (4.79 g, 11.2 mmol, 82.7%yield) was obtained as a yellow oil.
Step 2: (S) -1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid (f-4)
To a solution of (S) -methyl 1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oate, f-3 (4.79 g, 11.2 mmol) in mixture of tetrahydrofuran (20.0 mL) and water (20.0 mL) was added lithium hydroxide monohydrate (942 mg, 22.4 mmol) , the mixture was stirred at 25 ℃ for 2 hrs. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. Acetic acid was added to acidic, then ammonium was added to base, then (2, 5-dioxopyrrolidin-1-yl) 9H-fluoren-9-ylmethyl carbonate (8.21 g, 24.3 mmol) and sodiu hydrogen carbonate (2.04 g, 24.3 mmol) were added. The mixture was stirred at 25 ℃ for 2 hr.LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. TLC (Dichloromethane /Methanol = 10: 1, Rf = 0.3) showed raw material was consumed and one new spot was formed. The reaction mixture was concentrated under reduced pressure to remove water and tetrahydrofuran to give a residue. The crude product was purified by column chromatography (SiO2, Dichloromethane/Methanol=100/1 to 20/1) to give (S) -1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid, f-4 (1.25 g, 3.03 mmol, 12.45%yield) as light yellow liquid as light yellow oil.
Step 3: (11S) -11-benzyl-24- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-7, 10, 13, 16-tetraoxo-19- (trifluoromethyl) -4-oxa-6, 9, 12, 15, 18-pentaazatetracosan-1-oic acid (f-5, i.e., L-1-4)
To a mixture containing CTC-Resin (1.5 g, 1.50 mmol) and (S) -1- (9H-fluoren-9-yl) -11-methyl-3, 6-dioxo-2, 9-dioxa-4, 7-diazadodecan-12-oic acid, f-4 (0.60 g, 1.50 mmol) , N, N-diisopropylethylamine (DIEA) (6.00 mmol) , dichloromethane (10.0 mL) were added into swell. The resin was mixed for 2 hrs, then methanol (5.00 mL) was added and mixed for 30 mins. And then, the resin was washed with N, N-Dimethylformamide (10.0 mL) for 5 times. The resin was treated with 20%piperidine in N, N-Dimethylformamide for 30 mins for Fmoc deprotection. The resin was washed with N, N-Dimethylformamide for 3 times. Then Fmoc-Phe-OH (4.50 mmol) was added and mixed for 30 secs, then O-Benzotriazole-N, N, N, N-tetramethyl-uronium-hexafluorophosphate (HBTU) (4.50 mmol) and N, N-diisopropylethylamine (DIEA) (9.00 mmol) in N, N-Dimethylformamide were added and bubbled by N2 for 30 mins. The resin was washed with N, N-Dimethylformamide for 3 times. The above step was repeated for next amino acid Fmoc-Gly-OH (4.50 mmol) and special
amino acid, 2- ( (7- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -1, 1, 1-trifluoroheptan-2-yl) amino) acetic acid (0.20 g, 1.31 mmol) coupling at 25℃. The reaction was detected by ninhydrin test. The coupling reaction was monitored by ninhydrin color reaction. After washing with methanol 10.0 mL and drying under vacuum, 20.0 mL of cleavage buffer (20%HFIP/80%DCM) was added to the flask containing the resin of peptide stirred for 2 mins for 2 times. The HFIP-mixture was removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%H2O/CH3CN on C-18 column chromatography) . Then the resulting product was freeze-dried to give (11S) -11-benzyl-24- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-7, 10, 13, 16-tetraoxo-19- (trifluoromethyl) -4-oxa-6, 9, 12, 15, 18-pentaazatetracosan-1-oic acid, f-5 (167 mg, 9.80%yield) as a white solid.
Step 4: (Deruxtecan analog 1-4)
To a mixture of (11S) -11-benzyl-24- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-7, 10, 13, 16-tetraoxo-19- (trifluoromethyl) -4-oxa-6, 9, 12, 15, 18-pentaazatetracosan-1-oic acid, f-5 (20.0 mg, 28.6 umol) and 1-hydroxy-7-azabenzotriazole (HOAt) (7.79 mg, 57.2 umol) in N, N-Dimethylformamide (0.50 mL) was added Exatecan mesylate (15.2 mg, 28.6 umol) and N, N-diisopropylcarbondiimide (DIC) (21.6 mg, 171 umol, 26.5 uL) and N, N-diisopropylethylamine (DIEA) (7.40 mg, 57.2 umol, 9.97 uL) , then the mixture was stirred at 25 ℃ for 3 hrs. LC-MS showed raw material was consumed completely and one main peak with desired mass was detected. The reaction mixture was filtered to remove the undissolved residue. The residue was purified by prep-HPLC (TFA condition) . Then the resulting product was freeze-dried to give Deruxtecan analog 1-4 (6 mg, 5.20 umol, 18.1%yield, 96.2%purity) as a light yellow solid.
Synthesis of compound 1-8 (also called Deruxtecan analog 1-8 in FIG. 7)
Step 1: benzyl 2- (2- (benzyloxy) ethoxy) propanoate (g-2)
To a stirred DMF (100 mL) was added NaH (3.33 g, 83.2 mmol, 60%purity) in batches at 0 ℃ under N2. Benzyl (2S) -2-hydroxypropanoate (d-2, 10.0 g, 55.5 mmol) was added to above solution dropwise at 0 ℃ and stirred at 25 ℃ for 0.5 hrs. Then, 2-bromoethoxymethylbenzene (14.3 g, 66.6 mmol) was added to above solution at 0 ℃. The reaction was stirred at 25 ℃ for 16 hrs. TLC (Petroleum ether /Ethyl acetate = 5: 1, Rf = 0.2) showed the reaction was complete. The reaction mixture was quenched by addition water (1000 mL) at 0℃, and extracted with dichloromethane (200 mL x 3) . The combined organic layers were washed with brine (200 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silica gel, Petroleum ether/Ethyl acetate = 50/1 to 5/1) to give benzyl 2- (2- (benzyloxy) ethoxy) propanoate, g-2 (790 mg, 4.53%yield) as a
colorless oil. δ ppm 7.29 -7.43 (m, 10 H) , 5.10 -5.30 (m, 2 H) , 4.58 (d, g=2.01 Hz, 2 H) , 4.14 (q, g=6.86 Hz, 1 H) , 3.75 -3.87 (m, 1 H) , 3.60 -3.73 (m, 3 H) , 1.47 (d, g=7.03 Hz, 3 H) .
Step 2: 2- (2-hydroxyethoxy) propanoic acid (g-3)
The 100 mL round-bottom flask was purged with Ar for 3 times and added with dry Pd/C (160 mg) carefully. Then methanol (~10.0 mL) was added to infiltrate the Pd/C completely, followed by the solution benzyl (2S) -2- (2-benzyloxyethoxy) propanoate, g-2 (790 mg, 2.51 mmol) in MeOH (20.0 mL) slowly under Ar. The resulting mixture was degassed and purged with H2 for 3 times, and then the mixture was stirred at 25 ℃ for 4 hrs under H2 atmosphere. TLC (Petroleum ether /Ethyl acetate = 5: 1, Rf = 0.2) showed the reaction was complete. The reaction was filtered and concentrated under reduced pressure to give a product 2- (2-hydroxyethoxy) propanoic acid, g-3 (320 mg, crude) as light yellow liquid, the crude product was used for next step directly without purification. 1H NMR (400 MHz, DMSO) : δ ppm 4.02 (q, g=6.78 Hz, 1 H) , 3.66 -3.70 (m, 2 H) , 3.60 -3.66 (m, 1 H) , 3.49 -3.56 (m, 1 H) , 1.39 (d, g=7.03 Hz, 3 H) .
Step 3: benzyl 2- (2-hydroxyethoxy) propanoate (g-4)
To a solution of (2S) -2- (2-hydroxyethoxy) propanoic acid, g-3 (320 mg, 2.39 mmol) in MeOH (4 mL) and H2O (0.8 mL) was added Cs2CO3 (389 mg, 1.19 mmol) . The mixture was stirred at 25 ℃ for 0.5 hrs and concentrated. Then bromomethylbenzene (449 mg, 2.62 mmol) and DMF (2 mL) was added. The mixture was stirred at 25 ℃ for 16 hrs. TLC (Petroleum ether /Ethyl acetate = 3: 1, Rf = 0.4) showed the reaction was complete. The mixture was diluted with water (50.0 mL) and extracted with DCM (30 mL x 3) . The combined organic layers were dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (100-200 mesh silica gel) eluted with (Petroleum ether /Ethyl acetate =20/1 to 5/1) to give benzyl 2- (2-hydroxyethoxy) propanoate, g-4 (340 mg, 64%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.37 (s, 5 H) , 5.15 -5.26 (m, 2 H) , 4.04 -4.15 (m, 1 H) , 3.71 -3.76 (m, 2 H) , 3.60 -3.68 (m, 2 H) , 1.46 (d, g=7.03 Hz, 3 H) .
Step 4: benzyl 1- (9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate (g-6)
To a solution of [ [2- (9H-fluoren-9-ylmethoxycarbonylamino) acetyl] amino] methyl acetate (a-3) (614 mg, 1.67 mmol) in THF (8 mL) was added TsOH. H2O (14.4 mg, 75.8 umol) and benzyl 2- (2-hydroxyethoxy) propanoate, g-4 (340 mg, 1.52 mmol) . The mixture was stirred at 25 ℃ for 6 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue
was diluted with Sat. NaHCO3 (50 mL) and extracted with DCM (30 mL x 3) . The combined organic layers were washed with brine (30 mL) , dried over Na2SO4 filtered and concentrated under reduced pressure to give a residue. TLC (Petroleum ether /Ethyl acetate = 1: 1, Rf = 0.4) showed the reaction was complete. The residue was purified by column chromatography on silica gel (100-200 mesh silica gel) eluted with (Petroleum ether /Ethyl acetate =20/1 to 5/1) to give benzyl 1-(9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate, g-6 (416 mg, 781 umol, 51.5%yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ ppm 7.77 (d, g=7.53 Hz, 2 H) , 7.61 (br d, g=7.28 Hz, 2 H) , 7.39 -7.43 (m, 2 H) , 7.28 -7.38 (m, 7 H) , 7.21 (br s, 1 H) , 5.53 (br s, 1 H) , 5.19 (s, 2 H) , 4.93 -5.03 (m, 1 H) , 4.67 (br s, 1 H) , 4.44 (d, g=7.03 Hz, 2 H) , 4.22 -4.27 (m, 1 H) , 4.05 (q, g=7.03 Hz, 1 H) , 3.92 (br s, 2 H) , 3.76 (br s, 1 H) , 3.71 (br d, g=9.03 Hz, 2 H) , 3.55 (br d, g=8.53 Hz, 1 H) , 1.44 (d, g=6.78 Hz, 3 H) .
Step 5: 1- (9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oic acid (g-7)
The 100 mL round-bottom flask was purged with Ar for 3 times and added with dry Pd/C (60 mg) carefully. Then THF (5 mL) was added to infiltrate the Pd/C completely, followed by the solution of benzyl 1- (9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oate, g-6 (416 mg, 781 umol) in THF (10 mL) slowly under Ar. The resulting mixture was degassed and purged with H2 for 3 times, and then the mixture was stirred at 2 hrs 25 ℃ for 2 hrs under H2 (15 psi) . TLC (Petroleum ether /Ethyl acetate = 1: 1, Rf = 0.4) showed the reaction was complete. The reaction was filtered and concentrated under reduced pressure to give a product 1-(9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oic acid, g-7 (320 mg, 92.6%yield) as white gum, the crude product was used in next step without purification. 1H NMR (400 MHz, CDCl3) : δ ppm 7.77 (d, g=7.53 Hz, 2 H) , 7.60 (br d, g=7.28 Hz, 2 H) , 7.38 -7.44 (m, 2 H) , 7.29 -7.35 (m, 2 H) , 5.48 -5.65 (m, 1 H) , 4.95 (br s, 1 H) , 4.70 (dd, g=10.54, 6.02 Hz, 1 H) , 4.42 -4.52 (m, 2 H) , 4.23 (t, g=6.78 Hz, 1 H) , 4.02 (q, g=6.86 Hz, 1 H) , 3.94 (br s, 1 H) , 3.83 -3.92 (m, 1 H) , 3.75 -3.82 (m, 2 H) , 3.73 (br d, g=6.78 Hz, 2 H) , 3.58 -3.67 (m, 1 H) , 1.42 -1.48 (m, 3 H) .
Step 6: (13S) -13-benzyl-26- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) -2-methyl-9, 12, 15, 18-tetraoxo-21- (trifluoromethyl) -3, 6-dioxa-8, 11, 14, 17, 20-pentaazahexacosan-1-oic acid (g-8, i.e., L-1-8)
Peptide Synthesis:
The peptide was synthesized using standard Fmoc chemistry.
1) Add DCM to the vessel containing CTC Resin (1.5 mmol, 1.5 g, Sub=1.01 mmol/g) and 1- (9H-fluoren-9-yl) -13-methyl-3, 6-dioxo-2, 9, 12-trioxa-4, 7-diazatetradecan-14-oic acid (0.6 g, 1.5 mmol 1.0 eq ) with N2 bubbling.
2) Add DIEA (4.0 eq) dropwise and mix for 2 hours.
3) Add MeOH (0.5 mL) and mix for 30 min.
4) Drain and wash with DMF for 5 times.
5) Add 20%piperidine/DMF and react on 30 min.
6) Drain and wash with DMF for 3 times.
7) Add Fmoc-amino acid solution and mix for 30 seconds, then add activation buffer, N2 bubbling for about 0.5hour.
8) Repeat step 5 to 7 for next amino acid coupling.
Note:
20%piperidine in DMF was used for Fmoc deprotection for 30 mins. The coupling reaction was monitored by ninhydrin test, and the resin was washed with DMF for 5 times.
Peptide Cleavage and Purification:
1) The resin was washed with MeOH for 3 times and dried by vacuum.
2) A cleavage buffer (20%HFIP /DCM) was added to the peptide Resin, and stirred for 0.5 hr for 3 times.
3) The DCM was concentrated under reduced pressure.
4) The peptide is dried in high vacuum for 2 hours to give the compound g-8 (100 mg, 90%) .
Step 7: (Deruxtecan analog 1-8)
To a solution of compound g-8 (20.0 mg, 27.5 umol) in DMF (200 uL) was added DIC (19.8 mg, 157 umol) , HOAT (7.12 mg, 52.3 umol) , (10S) -23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4, 15-diazahexacyclo [14.7.1.02, 14.04, 13.06, 11.020, 24] tetracosa-1, 6 (11) , 12, 14, 16 (24) , 17, 19-heptaene-5, 9-dione (13.9 mg, 26.1 umol, MsOH) and DIEA (6.76
mg, 52.3 umol) . The mixture was stirred at 25 ℃ for 8 hrs. LC-MS showed compound g-8 was consumed completely and one main peak with desired m/z was detected. Traces of N, N-Dimethylformamide were removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%water/acetonitrile on C-18 column chromatography) . Then the resulting product was freeze-dried to give compound Deruxtecan analog 1-8 (12 mg, 10.5 umol) as a yellow solid. LCMS (ESI, m/z) : 1145.4 [M+H] +: 1146.6 (Xbrige C18, 3.5 um, 2.1 x 30 mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (10-80_2 min) . HPLC (Gemini-NX C18 5um 110A 150 x 4.6mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (40-70_20+3 min) .
Synthesis of compound 3-4 (also called Deruxtecan analog 3-4 in FIG. 8)
Step 1: (S) -2-acetamido-6- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) hexanoic acid (h-3)
To a solution of (2S) -2-acetamido-6-amino-hexanoic acid (2.00 g, 10.6 mmol) in Sat NaHCO3 (50 mL) was added methyl 2, 5-dioxopyrrole-1-carboxylate (1.65 g, 10.6 mmol) . The mixture was stirred at 25 ℃ for 4 hrs. LC-MS showed compound h-1 was consumed completely and one main peak with desired m/z was detected. The reaction mixture was quenched by addition of H2SO4 at 0℃ to PH = 3-4, and then extracted with EA (100 mL x 3) . The combined organic layers were washed with brine (50 mL x 1) , dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silica gel, DCM/MeOH=100/1 to 20/1) to give (S) -2-acetamido-6- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) hexanoic acid, h-3 (460 mg, 1.71 mmol) . 1H NMR (400 MHz, CDCl3) : δ ppm 6.71 (s, 2 H) , 6.30 (br d, g=7.28 Hz, 1 H) , 4.48 -4.59 (m, 1 H) , 3.54 (t, g=6.78 Hz, 2 H) , 2.08 (s, 3 H) , 1.90 -2.00 (m, 1 H) , 1.75 -1.84 (m, 1 H) , 1.56 -1.70 (m, 2 H) , 1.31 -1.45 (m, 2 H) .
Step 2: (19S) -10-benzyl-19- (4- (2, 5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl) butyl) -6, 9, 12, 15, 18, 21-hexaoxo-3-oxa-5, 8, 11, 14, 17, 20-hexaazadocosan-1-oic acid (h-4, i.e., L-3-4)
Peptide Synthesis:
The peptide was synthesized using standard Fmoc chemistry.
1) Add DCM to the vessel containing CTC Resin (0.5 mmol, 0.5 g, Sub=1.01 mmol/g) and 1- (9H-fluoren-9-yl) -3, 6-dioxo-2, 9-dioxa-4, 7-diazaundecan-11-oic acid (0.2 g, 0.5 mmol, 1.0 eq ) with N2 bubbling.
2) Add DIEA (4.0 eq) dropwise and mix for 2 hours.
3) Add MeOH (0.5 mL) and mix for 30 min.
4) Drain and wash with DMF for 5 times.
5) Add 20%piperidine/DMF and react on 30 min.
6) Drain and wash with DMF for 3 times.
7) Add Fmoc-amino acid solution and mix for 30 seconds, then add activation buffer, N2 bubbling for about 0.5hour.
8) Repeat step 5 to 7 for next amino acid coupling.
Note:
20%piperidine in DMF was used for Fmoc deprotection for 30 mins. The coupling reaction was monitored by ninhydrin test, and the resin was washed with DMF for 5 times.
Peptide Cleavage and Purification:
1) The resin was washed with MeOH for 3 times and dried by vacuum.
2) Added cleavage buffer (20%HFIP /DCM) to the peptide Resin stirring for 0.5 hr for 3 times.
3) The DCM was concentrated under reduced pressure.
4) The peptide is dried in high vacuum for 2 hours to give compound h-4 (100 mg, 95%) .
Step 3: (Deruxtecan analog 3-4)
To a solution of compound h-4 (20.0 mg, 29.7 umol) in DMF (500 uL) was added DIC (15.6 mg, 124 umol) , EXATECAN MESYLATE (13.2 mg, 24.7 umol) and HOBt (3.68 mg, 27.2 umol) . The mixture was stirred at 25 ℃ for 16 hrs. TLC (DCM/MeOH = 10/1, Rf = 0.4) showed the reaction was complete. Traces of N, N-Dimethylformamide were removed in vacuum to give a residue. The residue was purified by Flash (Eluent of 10-50%water/acetonitrile on C-18 column chromatography) . Then the resulting product was freeze-dried to give compound Deruxtecan analog 3-4 (7 mg, 6.42 umol, ) as a yellow solid. LCMS (ESI, m/z) : 1090.4 [M+H] +: 1091.4 (Xbrige C18, 3.5 um, 2.1 x 30 mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA
in acetonitrile (10-80_2 min) . HPLC (Gemini-NX C18 5um 110A 150 x 4.6mm column, Wavelength: UV 220 nm &254 nm; Column temperature: 30 ℃) eluting with 0.1%TFA in water : 0.1%TFA in acetonitrile (25-55_20+3 min) .
(d) Synthesis of the ″Native Linker-payload″
In the context of the present disclosure, the term ″native linker-payload″ (also referred to as ″native-LP″ or ″nat-LP″ herein below) refers to a compound having the following structure:
The native-LP has the same structure as Deruxtecan in Enhertu, both containing the maleimide-GGFG pepetide linker. In this example, the native-LP was purchased under the name ″Deruxtecan″ from MedChemExpress.
Example 2: Synthesis of Antibody-drug Conjugates
Antibody-drug conjugates were synthesized according the following general procedure: an antibody in a pH7 PBS solution was first reduced by 2~20 equivalent of TCEP for a period of time raging from 0.5 to 18 hrs; with or without removal of residual TCEP by column or membrane, a linker-load in excess (15~18 molar excess) was introduced; the conjugation reaction was finished in half to several hours at a temperature ranging from 4℃ to RT, followed by HPLC purification to provide the final ADC product.
Notes: 1: Expressed as Ab followed by the numeral code for each Linker-payload moiety
2: Molar ratio
3: Also termed ″Her-Dxd″ or ″Her-nat-LP″ herein below
Example 3: Cleavage of Linker-payloads
Method
Reaction buffer (40 mM H3PO4/H3BO3/HAc, 1 mM EDTA, pH 4.5) , 135 mM Cysteine, DMA (N, N’ -Dimethylacetamide, 2%, v/v) , sample (0.015 μmol linker-payload compound) and cathepsin B (16 U/μmol linker-payload compound) were added in sequence into a 1.5 mL EP vial. The final cysteine concentration in thus obtained 300 μL hydrolysis system was 10 mM. The EP vial was placed in a 37℃ water bath.
After hydrolysis for around 15min, 2 hr, 5 hr and 16 hr, the mixture was vortexed well and then sampled (25 μL) . Into the sampled mixture, Cathepsin B inhibitor E64 (2.5 equivalent to cathepsin B) was added to deactivate cathepsin B before analysis by RP-HPLC and RP-MS. Cleavage percentages were calculated from the peak area of the hydrolyzed linker-payload relative to the area sum of the non-hydrolyzed plus the hydrolyzed, as detected by RP-HPLC or RP-MS.
Results
Digestion (expressed in percentages) along a time period of around 16 hours (overnight) were summarized in Table 1, which showed a comparison of digestion efficiency by cathespin B among linker-payloads. As seen, all the tested linker-payloads of the invention were digested faster than
or at least comparable to (as observed with Compound 3-1) the native linker-payload.
Table 1
In FIG. 9, cleavage site and modification on the linker moiety in Compound 1-1 were indicated in panel (a) , as in comparison with the native linker-payload; and percentages (%) of cleavage are shown in panel (b) , wherein the percentages were calculated based on the peak areas of released drugs as detected by reverse-phase HPLC (mixed mode) chromatogram. In consistency with the results in Table 1, the linker-payloads of the invention were digested faster.
Example 4: Cleavage of Linker-payload moiety in ADC
Method
The reaction conditions were set the same as in Example 3 for hydrolysis of linker-payloads per se. Specifically, reaction buffer (40 mM H3PO4/H3BO3/HAc, 1 mM EDTA, pH 4.5) , 135 mM Cysteine, DMA (2%, v/v) , sample (0.015 μmol ADC) and cathepsin B (16 U/μmol ADC) were added in sequence into a 1.5 mL EP vial. The final cysteine concentration in the 300 μL hydrolysis system was 10 mM. The EP vial was placed in a 37℃ water bath.
After hydrolysis for 10min, 5 hr, 24 hr and 48 hr, the mixture was vortexed well and then 25 μL sampled. Into the sampled mixture, Cathepsin inhibitor E64 (2.5 equivalent to cathepsin B) was added to deactivate cathepsin B before analysis by reverse-phase LC-MS. The hydrolysis rate was calculated based on the decrease of DAR determined from MS spectra.
Results
Percentages of digestion over time were summarized in Table 2, which showed a comparison
of digestion efficiency by cathepsin B among different linker-payload moieties in ADCs. It is clear that ADCs comprising linker-payload moieties 1-2, 1-3, 3-1 and 3-4 had faster drug release rates in the presence of cathepsin B. Interestingly in a separated hydrolysis experiment where mixed mode column was used to quantitate the released drug via cleavage, we observed that the ADC comprising linker-payload moiety 1-1 released the drug slightly faster than the ADC comprising the native linker-payload.
Table 2
In FIG. 10, cleavage site and modification in comparison with the native linker-payload moiety in ADC are indicated in panel (a) , and percentage (%) of cleavage of the linker-payloads in ADCs over time is shown in panel (b) , wherein the percentages were calculated based on the peak areas of released drugs (supra) . At 48hr, the hydrolysis percentage was 18.5%for ADC-1-1 (i.e. ADC comprising linker-payload moiety 1-1) , while 15.5%for ADC-native LP.
Example 5: Freeze-Thaw Stability
Method
ADC samples (~10mg/mL in 20 mM Histidine, 150mM NaCl, pH6.0) in Eppendorf tubes were taken out from a -80℃ freezer and thawed at room temperature for 30 min. The ADC samples were then frozen at -80℃ for 2 days and thawed at room temperature for 30 min; and the freeze/thaw process was repeated one more time. After that, 20 μl of each sample was subjected to SEC and MS to measure DAR and drug distribution. Percentages (molar ratio) of each species (L0, L1, L2, H0, H1, H2, H4, etc., wherein ″L″ refers to light chain, ″H″ refers to heavy chain, and the numeral refers to the number of drug molecules linked onto the chain) in each sample were determined based on peak areas of the species.
Results
Changes in the unwanted species, i.e., L2 (ADCs with two drug molecules linked on the light chain) and H4 (ADCs with four drug molecules linked on the heavy chain) , and in DAR after two freeze-and-thaw (F/T) cycles were summarized in Table 3. As seen, for the ADCs comprising the linker-payload moieties according to the invention, the L2 species remained zero (0) after two freeze-and-thaw cycles, while for Her-Dxd (i.e., Trastuzumab deruxtecan) , the L2 species rose to 0.76%. The H4%in Her-Dxd was also the highest. The ADC comprising linker-payload moiety 1-8 exhibited the lightest DAR drop after two freeze-and-thaw cycles. Overall, the eight ADC analogs all contained less undesired H4 than Her-Dxd while maintained stable DAR after Freeze-and-thaw cycles.
Table 3
Note: ″Her″ = ″Herceptin″ , aka. ″Trastuzumab″ ; and ″Fresh″ refers to the samples of newly synthesized ADCs that were not subjected to the freeze-and-thaw cycles yet.
Example 6: Detection of H4 species in ADCs
Method
ADCs were formulated in 20 mM Histidine buffer comprising 150mM NaCl, pH6.0. The obtained ADC samples were subjected to LC-MS analysis to determine drug distribution on light and heavy chains. Ideally, only 5 species, L0, H0, L1, H1 and H2, can be found. Aggregation percentage was determined by HPLC.
Results
Table 4 shows a comparison of the non-specific and unwanted H4%among ADCs. In the case of Trastuzumab deruxtecan using the native linker-payload, i.e., the Her-Dxd control, H4%(molar ratio) was 3%after synthesis, while in the case of Her-1-8, the unwanted species was significantly decreased to 0.8%. As seen, ADC products produced with the linker-payloads of the invention contain less unwanted species.
Table 4
Example 7: Removal of un-conjugated linker-payloads
After conjugation as described in Example 2, the ADCs were buffer exchanged into 20 mM Histidine buffer comprising 150mM NaCl (pH6.0) via spin desalting column (40 kDa) . In Table 5, is a comparison among ADCs using different linker-payloads on removal of free linker-payloads (i.e., un-conjugated linker-payloads) . The free linker-payloads were removed via UFDF. In the case of Her-Dxd (i.e., Trastuzumab deruxtecan) , the conjugation product had an amount of residual free linker-payload approaching 5%, while in the case of products produced using the linker-payloads of the invention, the amount was 2%or less.
As seen, the linker-payloads of the invention provide improved operability in purification, for instance, by allowing for an easier and more complete removal of residual free linker-payloads from an ADC conjugation product. Without being limited to any particular theories, it is believed that introduction of the dipolar moiety to the linker moiety increases water solubility of the linker-payload and facilitates its removal, e.g., by UFDF. This property is meaningful for the process of ADC manufacturing.
Table 5
Example 8: Binding Assay
Method
Binding to human HER2 in vitro were assayed by FACS (Fluorescence Activated Cell Sorting) . On the assay day, tumor cells expressing HER-2 (1×105 cells/well) were incubated with serially-diluted ADCs for 1-2 hours at 4℃. Her-Dxd, prepared as described in Example 2, was used as the reference ADC and positive control. The buffer used to dissolve the ADCs (20 mM Histidine buffer comprisng 150mM NaCl (pH6.0) ) was used as the negative control. After incubation, the cells were washed with the FACS staining buffer, and then the secondary antibody
Alexa647-conjugated goat anti-human IgG Fc (Jackson) diluted in the FACS staining buffer was added. The plates were incubated at 4℃ for 20-60 minutes in dark. Then, fluorescence intensity was measured on flow cytometer (BD FACS Canto II) and data analyzed by FlowJo software. The EC50 values were calculated using GraphPad Prism software.
Result
Results were shown in FIG. 11. As tested on N87 cells, the test ADCs of the invention were observed with an EC50 around 1nM, while 0.9 nM for Her-Dxd. As tested on JIMT-1 cells, the test ADCs of the invention were observed with an EC50 of 0.4~0.7nM, while 0.4 nM for Her-Dxd. As tested on MDA-MB-231 cells, the test ADCs of the invention (except for Her3-1) were observed with an EC50 of 0.5~0.7 nM, while 0.6 for Her-Dxd. As seen, the ADCs of the invention, featuring the linkers and the linker-payloads of the invention, provided at least comparable or even better binding affinity compared with trastuzumab deruxtecan.
Example 9: Cytotoxicity Assay
Method
The ability to inhibit tumor cells growth was measured by cytotoxicity assay in vitro. Tumor cell lines (purchased from ATCC) , NCI-N87, HCC1954, MDA-MB-231 and JIMT-1 cells, were routinely cultured in RPMI1640 medium or DMEM medium. The day before the assay day, cells were seeded into 96-well plates in the culture medium at appropriate cell densities. On the next day, ADCs were serially diluted in the culture medium and added to each well. Her-Dxd prepared as described in Example 2 was used as the reference ADC and positive control. The buffer to dissolve ADCs was used as the negative control. The plates were then kept at 37℃ and 5%CO2 in incubator. After 4-6 days, cell viability was tested using CellTiter-Glo (Promega) . The IC50 values were calculated using GraphPad Prism software.
Result
Results are shown in FIG. 12. While neither the test ADCs of the invention nor Her-Dxd were observed with active cytotoxicity on JIMT-1 and MDA-MB-231 cells (IC50 >1nM) , in N87 and HCC1954 cells, all the test ADCs of the invention showed cytotoxicity comparable to the native ADC, with IC50 being around 0.1 nM. As seen, the ADCs of the invention, featuring the linkers and the linker-payloads of the invention, provided at least comparable cytotoxicity as compared to trastuzumab deruxtecan.
Claims (18)
- A compound of formula I:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof;wherein, ″*″ indicates a chiral center, which is S-or R-or racemic; and the hydrogen atom attached to the chiral carbon atom and the hydrogen atom attached to the carbon atom with a R2 substituent are omitted from the formula;L1 is - (CH2) a-, wherein a is an integer from 0 to 10, or - (CH2CH2O) b-, wherein b is an integer from 1 to 36;L2 is - (CH2) c-, wherein c is an integer from 1 to 10, or - (CH2CH2O) d-, wherein d is an integer from 1 to 36;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 10, or - (CH2CH2O) f-, wherein f is an integer from 1 to 36;R1 is -CF3, -NRaRb, -NRa (C=O) Rb, or -O (CH2) gCH3, wherein g is an integer from 0 to 3, Ra is H, or -C1-6 alkyl, Rb is H or -C1-6 alkyl;R2 is -H, -C1-6 alkyl, or -O (CH2) hCH3, wherein h is an integer from 0 to 3;X is halo, -OR3 or -NR4R5;R3 is -H, -C1-6 alkyl or halo;R4 and R5 are independently -H or -C1-6 alkyl;n= 0 or 1; andm= 0 or 1. - The compound of claim 1, wherein L1 is - (CH2) a-, wherein a is an integer from 2 to 6;L2 is - (CH2) c-, wherein c is an integer from 1 to 6;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 6, or - (CH2CH2O) f-, wherein f is an integer from 1 to 20;R1 is -CF3, -N (CH3) 2, -NH (C=O) CH3, or -O (CH2) 2CH3;R2 is -H, or -C1-6 alkyl; and/orR3 is -H, -CH3, t-butyl or Cl.
- The compound of claim 1, wherein L1 is - (CH2) a-, wherein a is an integer from 4 to 5;L2 is - (CH2) c-, wherein c is an integer from 1 to 2;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 2, or - (CH2CH2O) f-, wherein f is an integer from 1 to 2;R1 is -CF3, -N (CH3) 2, or -NH (C=O) CH3;R2 is -H, or -CH3; and/orR3 is -H, -CH3, t-butyl or Cl.
- The compound of claim 1, wherein the compound is selected from the groups consisting of L-1-1, L-1-2, L-1-3, L-1-4, L-1-7, L-1-8, L-3-1 and L-3-4 as shown below, or a pharmaceutically acceptable salt or ester thereof:
wherein ″*″ indicates a chiral center, which is racemic. - A conjugate compound of formula II:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof;wherein, ″*″ indicates a chiral center, which is S-or R-or racemic; and the hydrogen atom attached to the chiral carbon atom and the hydrogen atom attached to the carbon atom with a R2 substituent are omitted from the formula;L1 is - (CH2) a-, wherein a is an integer from 0 to 10, or - (CH2CH2O) b-, wherein b is an integer from 1 to 36;L2 is - (CH2) c-, wherein c is an integer from 1 to 10, or - (CH2CH2O) d-, wherein d is an integer from 1 to 36;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 10, or - (CH2CH2O) f-, wherein f is an integer from 1 to 36;R1 is -CF3, -NRaRb, -NRa (C=O) Rb, or -O (CH2) gCH3, wherein g is an integer from 0 to 3, Ra is H, or -C1-6 alkyl, Rb is H or -C1-6 alkyl;R2 is -H, -C1-6 alkyl, or -O (CH2) hCH3, wherein h is an integer from 0 to 3;n= 0 or 1;m= 0 or 1; and″DRUG″ is a drug moiety covalently conjugated to the linker moiety. - The conjugate compound of claim 5, wherein L1 is - (CH2) a-, wherein a is an integer from 2 to 6;L2 is - (CH2) c-, wherein c is an integer from 1 to 6;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 6, or - (CH2CH2O) f-, wherein f is an integer from 1 to 20;R1 is -CF3, -N (CH3) 2, -NH (C=O) CH3, or -O (CH2) 2CH3; and/orR2 is -H, or -C1-6 alkyl.
- The conjugate compound of claim 5, wherein L1 is - (CH2) a-, wherein a is an integer from 4 to 5;L2 is - (CH2) c-, wherein c is an integer from 1 to 2;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 2, or - (CH2CH2O) f-, wherein f is an integer from 1 to 2;R1 is -CF3, -N (CH3) 2, or -NH (C=O) CH3; and/orR2 is -H, or -CH3.
- A conjugate compound according to claim 5, having the structure of formula IIa:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof; wherein, ″*″ , L1, L2, L3, R1, R2, n and m are define as in claim 5. - A conjugate compound according to claim 5, having a structure selected from the group consisting of:
wherein ″*″ indicates a chiral center, which is racemic. - An antibody-drug conjugate of formula III:
an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt or ester thereof;wherein, ″*″ indicates a chiral center, which is S-or R-or racemic and the hydrogen atom attached to the chiral carbon atom and the hydrogen atom attached to the carbon atom with a R2 substituent are omitted from the formula;L1 is - (CH2) a-, wherein a is an integer from 0 to 10, or - (CH2CH2O) b-, wherein b is an integer from 1 to 36;L2 is - (CH2) c-, wherein c is an integer from 1 to 10, or - (CH2CH2O) d-, wherein d is an integer from 1 to 36;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 10, or - (CH2CH2O) f-, wherein f is an integer from 1 to 36;R1 is -CF3, -NRaRb, -NRa (C=O) Rb, or -O (CH2) gCH3, wherein g is an integer from 0 to 3, Ra is H, or -C1-6 alkyl, Rb is H or -C1-6 alkyl;R2 is -H, -C1-6 alkyl, or -O (CH2) hCH3, wherein h is an integer from 0 to 3;n= 0 or 1;m= 0 or 1;″DRUG″ is a drug moiety covalently conjugated to the linker moiety;p is 1 to 8, andAb is an antibody. - The antibody-drug conjugate of claim 10, wherein L1 is - (CH2) a-, wherein a is an integer from 2 to 6;L2 is - (CH2) c-, wherein c is an integer from 1 to 6;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 6, or - (CH2CH2O) f-, wherein f is an integer from 1 to 20;R1 is -CF3, -N (CH3) 2, -NH (C=O) CH3, or -O (CH2) 2CH3;R2 is -H, or -C1-6 alkyl; and/orp is 2, 4, or 6.
- The antibody-drug conjugate of claim 10, wherein L1 is - (CH2) a-, wherein a is an integer from 4 to 5;L2 is - (CH2) c-, wherein c is an integer from 1 to 2;L3 is absent, or is - (CH2) e-, wherein e is an integer from 1 to 2, or - (CH2CH2O) f-, wherein f is an integer from 1 to 2;R1 is -CF3, -N (CH3) 2, or -NH (C=O) CH3;R2 is -H, or -CH3;″DRUG″ is exatecan;p is 4; and/orAb is Trastuzumab.
- The antibody-drug conjugate of claim 10, having a structure selected from the group consisting of:
wherein ″*″ indicates a chiral center, which is racemic. - The antibody-drug conjugate of claim 13, wherein p is 2 4, or 6; and/or Ab is Trastuzumab.
- A method of producing a linker-payload compound, comprising conjugating a drug with the compound according to claim 1.
- The method of claim 15, wherein the drug is exatecan.
- A method of producing an antibody-drug-conjugate, comprising:(a) conjugating a drug with the compound according to claim 1 to obtain a linker-payload compound; and(b) conjugating an antibody with the linker-payload compound obtained in step (a) .
- The method of claim 17, wherein the drug is exatecan.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2022/103893 | 2022-07-05 | ||
CN2022103893 | 2022-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024008102A1 true WO2024008102A1 (en) | 2024-01-11 |
Family
ID=88049575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/105774 WO2024008102A1 (en) | 2022-07-05 | 2023-07-04 | Linker for conjugation |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN116789733A (en) |
TW (1) | TW202402736A (en) |
WO (1) | WO2024008102A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104755494A (en) * | 2012-10-11 | 2015-07-01 | 第一三共株式会社 | Antibody-drug conjugate |
CN105073139A (en) * | 2013-02-14 | 2015-11-18 | 百时美施贵宝公司 | Tubulysin compounds, methods of making and use |
CN106163559A (en) * | 2014-04-10 | 2016-11-23 | 第三共株式会社 | Anti-HER3 antibody drug conjugates |
WO2018066626A1 (en) * | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
CN111936169A (en) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | Camptothecin peptide conjugates |
CN112138171A (en) * | 2019-06-28 | 2020-12-29 | 上海复旦张江生物医药股份有限公司 | Antibody coupling drug, intermediate thereof, preparation method and application |
WO2021190586A1 (en) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | B7h3 antibody-exatecan analogue conjugate and pharmaceutical use thereof |
WO2021249228A1 (en) * | 2020-06-08 | 2021-12-16 | 四川百利药业有限责任公司 | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
WO2022099762A1 (en) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | Antibody conjugate intermediate and preparation method therefor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3108754A1 (en) * | 2018-08-06 | 2020-02-13 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
MX2021003382A (en) * | 2018-09-26 | 2021-05-27 | Jiangsu Hengrui Medicine Co | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof. |
AU2020214507A1 (en) * | 2019-01-30 | 2021-08-19 | Coherent Biopharma (Suzhou), Limited | Bi-ligand drug conjugate and use thereof |
CN111689980A (en) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | Camptothecin drug and antibody conjugate thereof |
WO2020259258A1 (en) * | 2019-06-28 | 2020-12-30 | 上海复旦张江生物医药股份有限公司 | Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof |
CN112125915A (en) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | Camptothecin derivative and conjugate thereof |
CN115515644A (en) * | 2020-06-28 | 2022-12-23 | 昆山新蕴达生物科技有限公司 | Antibody-drug conjugate, preparation method and application thereof |
-
2023
- 2023-07-04 CN CN202310818694.9A patent/CN116789733A/en active Pending
- 2023-07-04 WO PCT/CN2023/105774 patent/WO2024008102A1/en unknown
- 2023-07-05 TW TW112125123A patent/TW202402736A/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104755494A (en) * | 2012-10-11 | 2015-07-01 | 第一三共株式会社 | Antibody-drug conjugate |
CN105073139A (en) * | 2013-02-14 | 2015-11-18 | 百时美施贵宝公司 | Tubulysin compounds, methods of making and use |
CN106163559A (en) * | 2014-04-10 | 2016-11-23 | 第三共株式会社 | Anti-HER3 antibody drug conjugates |
WO2018066626A1 (en) * | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
CN111936169A (en) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | Camptothecin peptide conjugates |
CN112138171A (en) * | 2019-06-28 | 2020-12-29 | 上海复旦张江生物医药股份有限公司 | Antibody coupling drug, intermediate thereof, preparation method and application |
WO2021190586A1 (en) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | B7h3 antibody-exatecan analogue conjugate and pharmaceutical use thereof |
WO2021249228A1 (en) * | 2020-06-08 | 2021-12-16 | 四川百利药业有限责任公司 | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
WO2022099762A1 (en) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | Antibody conjugate intermediate and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
CN116789733A (en) | 2023-09-22 |
TW202402736A (en) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7014856B2 (en) | Self-stabilizing linker conjugate | |
JP6328649B2 (en) | Drug-protein conjugate | |
TWI811726B (en) | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics | |
KR102076219B1 (en) | Tridentate connexon and use thereof | |
KR102051503B1 (en) | Stability-modulating linkers for use with antibody drug conjugates | |
KR20150119086A (en) | Tubulysin compounds, methods of making and use | |
CA3075218A1 (en) | Transglutaminase conjugation method and linker | |
EP3302570B1 (en) | Trimaleimide linkers and uses thereof | |
WO2022218331A1 (en) | Linkers, conjugates and applications thereof | |
US20220226490A1 (en) | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | |
KR102493853B1 (en) | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of manufacture and use | |
CN110575548A (en) | Antibody-drug conjugate targeting CD73 and preparation method and application thereof | |
EP3801629A1 (en) | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | |
EP3617221A1 (en) | Cytotoxin and conjugate, uses of same, and preparation method therefor | |
WO2024008102A1 (en) | Linker for conjugation | |
Hu et al. | Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates | |
US20210393789A1 (en) | Sulfatase-Cleavable Linkers for Antibody-Drug Conjugates | |
WO2024012569A9 (en) | Linkers, conjugates and applications thereof | |
WO2024078612A1 (en) | Linker-payload compound, conjugates and applications thereof | |
JP2023551203A (en) | Glycosidic double cleavage linkers for antibody-drug conjugates | |
WO2023083900A1 (en) | Conjugates comprising a phosphorus (v) and a drug moiety | |
CN116783208A (en) | Glycoside double cleavage linker for antibody-drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23834869 Country of ref document: EP Kind code of ref document: A1 |